Cover
Cover - shares | 9 Months Ended | |
Sep. 29, 2023 | Oct. 24, 2023 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Sep. 29, 2023 | |
Document Transition Report | false | |
Entity File Number | 001-33072 | |
Entity Registrant Name | Leidos Holdings, Inc. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 20-3562868 | |
Entity Address, Address Line One | 1750 Presidents Street, | |
Entity Address, City or Town | Reston, | |
Entity Address, State or Province | VA | |
Entity Address, Postal Zip Code | 20190 | |
City Area Code | 571 | |
Local Phone Number | 526-6000 | |
Title of 12(b) Security | Common stock, par value $.0001 per share | |
Trading Symbol | LDOS | |
Security Exchange Name | NYSE | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 137,506,428 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2023 | |
Document Fiscal Period Focus | Q3 | |
Entity Central Index Key | 0001336920 | |
Current Fiscal Year End Date | --12-29 |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Sep. 29, 2023 | Dec. 30, 2022 |
Assets: | ||
Cash and cash equivalents | $ 750 | $ 516 |
Receivables, net | 2,452 | 2,350 |
Inventory, net | 295 | 287 |
Other current assets | 494 | 490 |
Total current assets | 3,991 | 3,643 |
Property, plant and equipment, net | 935 | 847 |
Intangible assets, net | 713 | 952 |
Goodwill | 6,079 | 6,696 |
Operating lease right-of-use assets, net | 512 | 545 |
Other long-term assets | 527 | 388 |
Total assets | 12,757 | 13,071 |
Liabilities: | ||
Accounts payable and accrued liabilities | 2,221 | 2,254 |
Accrued payroll and employee benefits | 801 | 701 |
Short-term debt and current portion of long-term debt | 18 | 992 |
Total current liabilities | 3,040 | 3,947 |
Long-term debt, net of current portion | 4,667 | 3,928 |
Operating lease liabilities | 527 | 570 |
Deferred tax liabilities | 6 | 40 |
Other long-term liabilities | 314 | 233 |
Total liabilities | 8,554 | 8,718 |
Commitments and contingencies (Note 11) | ||
Stockholders’ equity: | ||
Common stock, $0.0001 par value, 500,000,000 shares authorized,137,506,136 and 136,926,990 shares issued and outstanding at September 29, 2023, and December 30, 2022, respectively | 0 | 0 |
Additional paid-in capital | 2,055 | 2,005 |
Retained earnings | 2,186 | 2,367 |
Accumulated other comprehensive loss | (95) | (73) |
Total Leidos stockholders’ equity | 4,146 | 4,299 |
Non-controlling interest | 57 | 54 |
Total stockholders' equity | 4,203 | 4,353 |
Total liabilities and stockholders' equity | $ 12,757 | $ 13,071 |
CONDENSED CONSOLIDATED BALANC_2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares | Sep. 29, 2023 | Dec. 30, 2022 |
Stockholders’ equity: | ||
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 500,000,000 | 500,000,000 |
Common stock, shares issued (in shares) | 137,506,136 | 136,926,990 |
Common stock, shares outstanding (in shares) | 137,506,136 | 136,926,990 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 29, 2023 | Sep. 30, 2022 | Sep. 29, 2023 | Sep. 30, 2022 | |
Income Statement [Abstract] | ||||
Revenues | $ 3,921 | $ 3,608 | $ 11,458 | $ 10,699 |
Cost of revenues | 3,334 | 3,095 | 9,809 | 9,136 |
Selling, general and administrative expenses | 239 | 232 | 709 | 730 |
Acquisition, integration and restructuring costs | 5 | 4 | 14 | 12 |
Goodwill impairment charges | 599 | 0 | 599 | 0 |
Asset impairment charges | 88 | 0 | 88 | 3 |
Equity earnings of non-consolidated subsidiaries | (8) | (4) | (21) | (5) |
Operating (loss) income | (336) | 281 | 260 | 823 |
Non-operating income (expense): | ||||
Interest expense, net | (53) | (50) | (163) | (148) |
Other income (expense), net | 1 | (10) | (4) | (7) |
(Loss) income before income taxes | (388) | 221 | 93 | 668 |
Income tax expense | (8) | (57) | (115) | (155) |
Net (loss) income | (396) | 164 | (22) | 513 |
Less: net income attributable to non-controlling interest | 3 | 2 | 8 | 5 |
Net (loss) income attributable to Leidos common stockholders | $ (399) | $ 162 | $ (30) | $ 508 |
Earnings per share: | ||||
Basic (in dollars per share) | $ (2.91) | $ 1.18 | $ (0.22) | $ 3.71 |
Diluted (in dollars per share) | $ (2.91) | $ 1.17 | $ (0.22) | $ 3.68 |
CONDENSED CONSOLIDATED STATEM_2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 29, 2023 | Sep. 30, 2022 | Sep. 29, 2023 | Sep. 30, 2022 | |
Statement of Comprehensive Income [Abstract] | ||||
Net (loss) income | $ (396) | $ 164 | $ (22) | $ 513 |
Foreign currency translation adjustments | (31) | (75) | (19) | (158) |
Unrecognized gain (loss) on derivative instruments | 0 | 18 | (1) | 54 |
Pension adjustments | (1) | 1 | (2) | (19) |
Total other comprehensive (loss) income, net of taxes | (32) | (56) | (22) | (123) |
Comprehensive (loss) income | (428) | 108 | (44) | 390 |
Less: net income attributable to non-controlling interest | 3 | 2 | 8 | 5 |
Comprehensive (loss) income attributable to Leidos common stockholders | $ (431) | $ 106 | $ (52) | $ 385 |
CONDENSED CONSOLIDATED STATEM_3
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - USD ($) $ in Millions | Total | Leidos stockholders' equity | Shares of common stock | Additional paid-in capital | Retained earnings | Accumulated other comprehensive income (loss) | Non-controlling interest |
Beginning balance (in shares) at Dec. 31, 2021 | 140,000,000 | ||||||
Beginning balance at Dec. 31, 2021 | $ 4,344 | $ 4,291 | $ 2,423 | $ 1,880 | $ (12) | $ 53 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Net (loss) income | 177 | 175 | 175 | 2 | |||
Other comprehensive income (loss), net of taxes | 32 | 32 | 32 | ||||
Issuances of stock (in shares) | 1,000,000 | ||||||
Issuances of stock | 15 | 15 | 15 | ||||
Repurchases of stock and other (in shares) | (4,000,000) | ||||||
Repurchases of stock and other | (526) | (526) | (526) | ||||
Dividends | (48) | (48) | (48) | ||||
Stock-based compensation | 16 | 16 | 16 | ||||
Net capital distributions to non-controlling interest | (2) | (2) | |||||
Ending balance (in shares) at Apr. 01, 2022 | 137,000,000 | ||||||
Ending balance at Apr. 01, 2022 | 4,008 | 3,955 | 1,928 | 2,007 | 20 | 53 | |
Beginning balance (in shares) at Dec. 31, 2021 | 140,000,000 | ||||||
Beginning balance at Dec. 31, 2021 | 4,344 | 4,291 | 2,423 | 1,880 | (12) | 53 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Net (loss) income | 513 | ||||||
Other comprehensive income (loss), net of taxes | (123) | ||||||
Ending balance (in shares) at Sep. 30, 2022 | 137,000,000 | ||||||
Ending balance at Sep. 30, 2022 | 4,139 | 4,086 | 1,982 | 2,239 | (135) | 53 | |
Beginning balance (in shares) at Apr. 01, 2022 | 137,000,000 | ||||||
Beginning balance at Apr. 01, 2022 | 4,008 | 3,955 | 1,928 | 2,007 | 20 | 53 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Net (loss) income | 172 | 171 | 171 | 1 | |||
Other comprehensive income (loss), net of taxes | (99) | (99) | (99) | ||||
Issuances of stock | 10 | 10 | 10 | ||||
Repurchases of stock and other | (2) | (2) | (2) | ||||
Dividends | (50) | (50) | (50) | ||||
Stock-based compensation | 19 | 19 | 19 | ||||
Net capital distributions to non-controlling interest | (1) | (1) | |||||
Ending balance (in shares) at Jul. 01, 2022 | 137,000,000 | ||||||
Ending balance at Jul. 01, 2022 | 4,057 | 4,004 | 1,955 | 2,128 | (79) | 53 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Net (loss) income | 164 | 162 | 162 | 2 | |||
Other comprehensive income (loss), net of taxes | (56) | (56) | (56) | ||||
Issuances of stock | 13 | 13 | 13 | ||||
Repurchases of stock and other | (4) | (4) | (4) | ||||
Dividends | (51) | (51) | (51) | ||||
Stock-based compensation | 18 | 18 | 18 | ||||
Net capital distributions to non-controlling interest | (2) | (2) | |||||
Ending balance (in shares) at Sep. 30, 2022 | 137,000,000 | ||||||
Ending balance at Sep. 30, 2022 | $ 4,139 | 4,086 | 1,982 | 2,239 | (135) | 53 | |
Beginning balance (in shares) at Dec. 30, 2022 | 136,926,990 | 137,000,000 | |||||
Beginning balance at Dec. 30, 2022 | $ 4,353 | 4,299 | 2,005 | 2,367 | (73) | 54 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Net (loss) income | 164 | 162 | 162 | 2 | |||
Other comprehensive income (loss), net of taxes | 9 | 9 | 9 | ||||
Issuances of stock | 14 | 14 | 14 | ||||
Repurchases of stock and other | (43) | (43) | (43) | ||||
Dividends | (50) | (50) | (50) | ||||
Stock-based compensation | 18 | 18 | 18 | ||||
Net capital distributions to non-controlling interest | (1) | (1) | |||||
Ending balance (in shares) at Mar. 31, 2023 | 137,000,000 | ||||||
Ending balance at Mar. 31, 2023 | $ 4,464 | 4,409 | 1,994 | 2,479 | (64) | 55 | |
Beginning balance (in shares) at Dec. 30, 2022 | 136,926,990 | 137,000,000 | |||||
Beginning balance at Dec. 30, 2022 | $ 4,353 | 4,299 | 2,005 | 2,367 | (73) | 54 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Net (loss) income | (22) | ||||||
Other comprehensive income (loss), net of taxes | $ (22) | ||||||
Ending balance (in shares) at Sep. 29, 2023 | 137,506,136 | 138,000,000 | |||||
Ending balance at Sep. 29, 2023 | $ 4,203 | 4,146 | 2,055 | 2,186 | (95) | 57 | |
Beginning balance (in shares) at Mar. 31, 2023 | 137,000,000 | ||||||
Beginning balance at Mar. 31, 2023 | 4,464 | 4,409 | 1,994 | 2,479 | (64) | 55 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Net (loss) income | 210 | 207 | 207 | 3 | |||
Other comprehensive income (loss), net of taxes | 1 | 1 | 1 | ||||
Issuances of stock | 14 | 14 | 14 | ||||
Dividends | (50) | (50) | (50) | ||||
Stock-based compensation | 19 | 19 | 19 | ||||
Net capital distributions to non-controlling interest | (5) | (3) | (3) | (2) | |||
Ending balance (in shares) at Jun. 30, 2023 | 137,000,000 | ||||||
Ending balance at Jun. 30, 2023 | 4,653 | 4,597 | 2,024 | 2,636 | (63) | 56 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Net (loss) income | (396) | (399) | (399) | 3 | |||
Other comprehensive income (loss), net of taxes | (32) | (32) | (32) | ||||
Issuances of stock (in shares) | 1,000,000 | ||||||
Issuances of stock | 12 | 12 | 12 | ||||
Repurchases of stock and other | (1) | (1) | (1) | ||||
Dividends | (51) | (51) | (51) | ||||
Stock-based compensation | 20 | 20 | 20 | ||||
Net capital distributions to non-controlling interest | $ (2) | (2) | |||||
Ending balance (in shares) at Sep. 29, 2023 | 137,506,136 | 138,000,000 | |||||
Ending balance at Sep. 29, 2023 | $ 4,203 | $ 4,146 | $ 2,055 | $ 2,186 | $ (95) | $ 57 |
CONDENSED CONSOLIDATED STATEM_4
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) - $ / shares | 3 Months Ended | |||||
Sep. 29, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Sep. 30, 2022 | Jul. 01, 2022 | Apr. 01, 2022 | |
Statement of Stockholders' Equity [Abstract] | ||||||
Dividends (in dollars per share) | $ 0.36 | $ 0.36 | $ 0.36 | $ 0.36 | $ 0.36 | $ 0.36 |
CONDENSED CONSOLIDATED STATEM_5
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions | 9 Months Ended | |
Sep. 29, 2023 | Sep. 30, 2022 | |
Cash flows from operations: | ||
Net (loss) income | $ (22) | $ 513 |
Adjustments to reconcile net (loss) income to net cash provided by operations: | ||
Depreciation and amortization | 248 | 249 |
Stock-based compensation | 57 | 53 |
Deferred income taxes | (192) | (221) |
Goodwill impairment charges | 599 | 0 |
Asset impairment charges | 88 | 3 |
Other | 25 | 21 |
Change in assets and liabilities, net of effects of acquisitions and dispositions: | ||
Receivables | (109) | (139) |
Other current assets and other long-term assets | 141 | 132 |
Accounts payable and accrued liabilities and other long-term liabilities | 22 | (70) |
Accrued payroll and employee benefits | 105 | 217 |
Income taxes receivable/payable | (101) | 109 |
Net cash provided by operating activities | 861 | 867 |
Cash flows from investing activities: | ||
Acquisition of a business, net of cash acquired | (6) | (2) |
Divestiture of a business | 0 | 15 |
Payments for property, equipment and software | (129) | (76) |
Net proceeds from sale of assets | 0 | 6 |
Other | 0 | 2 |
Net cash used in investing activities | (135) | (55) |
Cash flows from financing activities: | ||
Proceeds from debt issuance | 1,743 | 380 |
Repayments of borrowings | (2,041) | (459) |
Payments for debt issuance costs | (7) | 0 |
Dividend payments | (150) | (149) |
Repurchases of stock and other | (44) | (532) |
Proceeds from issuances of stock | 37 | 35 |
Net capital distributions to non-controlling interests | (8) | (5) |
Net cash used in financing activities | (470) | (730) |
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | 0 | 14 |
Net increase in cash, cash equivalents and restricted cash | 256 | 96 |
Cash, cash equivalents and restricted cash at beginning of period | 683 | 875 |
Cash, cash equivalents and restricted cash at end of period | 939 | 971 |
Less: restricted cash at end of period | 189 | 164 |
Cash and cash equivalents at end of period | 750 | 807 |
Supplementary cash flow information: | ||
Cash paid for income taxes, net of refunds | 325 | 166 |
Cash paid for interest | 160 | 136 |
Non-cash investing and financing activity: | ||
Property, plant and equipment additions | 2 | 7 |
Finance lease obligations | $ 65 | $ 1 |
Basis of Presentation and Summa
Basis of Presentation and Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 29, 2023 | |
Accounting Policies [Abstract] | |
Basis of Presentation and Summary of Significant Accounting Policies | Note 1–Basis of Presentation and Summary of Significant Accounting Policies Nature of Operations and Basis of Presentation Leidos Holdings, Inc. ("Leidos"), a Delaware corporation, is a holding company whose direct 100%-owned subsidiary and principal operating company is Leidos, Inc. Leidos is a FORTUNE 500 ® technology, engineering, and science company that provides services and solutions in the defense, intelligence, civil and health markets, both domestically and internationally. Leidos' customers include the U.S. Department of Defense ("DoD"), the U.S. Intelligence Community, the U.S. Department of Homeland Security, the Federal Aviation Administration, the Department of Veterans Affairs and many other U.S. civilian, state and local government agencies, foreign government agencies and commercial businesses. Unless indicated otherwise, references to "we," "us" and "our" refer collectively to Leidos Holdings, Inc. and its consolidated subsidiaries. We operate in three reportable segments: Defense Solutions, Civil and Health. Additionally, we separately present the unallocable costs associated with corporate functions as Corporate. We have a controlling interest in Mission Support Alliance, LLC ("MSA"), a joint venture with Centerra Group, LLC. We also have a controlling interest in Hanford Mission Integration Solutions, LLC ("HMIS"), the legal entity for the follow-on contract to MSA's contract and a joint venture with Centerra Group, LLC and Parsons Government Services, Inc. The financial results for MSA and HMIS are consolidated into our unaudited condensed consolidated financial statements. The unaudited condensed consolidated financial statements also include the balances of all voting interest entities in which Leidos has a controlling voting interest ("subsidiaries") and a variable interest entity ("VIE") in which Leidos is the primary beneficiary. The consolidated balances of the VIE are not material to the unaudited condensed consolidated financial statements for the periods presented. Intercompany accounts and transactions between consolidated companies have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements has been prepared in accordance with the rules of the U.S. Securities and Exchange Commission and accounting principles generally accepted in the United States of America ("GAAP"). Certain disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. Management evaluates these estimates and assumptions on an ongoing basis, including those relating to estimated profitability of long-term contracts, indirect billing rates, allowances for doubtful accounts, inventories, right-of-use assets and lease liabilities, fair value and impairment of intangible assets and goodwill, income taxes, stock-based compensation expense and contingencies. These estimates have been prepared by management on the basis of the most current and best available information; however, actual results could differ materially from those estimates. Certain amounts in the prior year financial statements have been reclassified to conform to the current year presentation. We combined "Bad debt expense and recoveries" into "Selling, general and administrative expenses" on the condensed consolidated statements of operations. We have certain entities where the functional currency is not the U.S. dollar and have separately presented the effect of exchange rate changes on cash, cash equivalents and restricted cash held in foreign currencies as a separate line in the condensed consolidated statements of cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, which consist of normal recurring adjustments, necessary for a fair presentation thereof. The results reported in these unaudited condensed consolidated financial statements are not necessarily indicative of the results that may be expected for the entire year. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Annual Report on Form 10-K filed on February 14, 2023. Accounting Standards Updates Issued and Adopted ASU 2020-04, ASU 2021-01 and ASU 2022-06, Reference Rate Reform (ASC 848) In March 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-04, which provides companies with optional expedients and exceptions to ease the potential accounting burden associated with transitioning away from reference rates that are expected to be discontinued. This update provides optional expedients for applying accounting guidance to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of the reference rate reform. The amendments in this update are effective for all entities as of March 2020 and can be adopted using a prospective approach no later than December 31, 2022. In January 2021, the FASB issued ASU 2021-01 which amends the scope of ASU 2020-04. The amendments in this update are elective and provide optional relief for entities with hedge accounting and contract modifications affected by the transition from LIBOR through December 31, 2022. In December 2022, the FASB issued ASU 2022-06 which extends the deadline for application of ASU 2021-01 through December 31, 2024. Under this relief, entities may continue to account for contract modifications as a continuation of the existing contract and the continuation of the hedge accounting arrangement. In the first half of fiscal 2023, we adopted certain practical expedients available under ASC 848. Our term loans are based on a Secured Overnight Financing Rate (“SOFR”) rate (see "Note 6–Debt"). Additionally, we modified our interest rate swap agreements to reference SOFR (see "Note 5–Derivative Instruments") in conformity with the relief available under ASC 848. The standard did not have a material impact on our financial position, results of operations or earnings per share. Changes in Estimates on Contracts Changes in estimates related to contracts accounted for using the cost-to-cost method of accounting are recognized in the period in which such changes are made for the inception-to-date effect of the changes, with the exception of contracts acquired through a business combination, where the adjustment is made for the period commencing from the date of acquisition. Changes in estimates on contracts were as follows: Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (in millions, except per share data) Favorable impact $ 40 $ 36 $ 102 $ 116 Unfavorable impact (24) (29) (62) (75) Net impact to (loss) income before income taxes $ 16 $ 7 $ 40 $ 41 Impact on diluted EPS attributable to Leidos common stockholders $ 0.09 $ 0.03 $ 0.22 $ 0.22 The impact on diluted earnings per share ("EPS") attributable to Leidos common stockholders is calculated using the statutory tax rate. Revenue Recognized from Prior Obligations Revenue recognized from performance obligations satisfied in previous periods was $13 million and $14 million for the three and nine months ended September 29, 2023, respectively, and $6 million and $38 million for the three and nine months ended September 30, 2022, respectively. The changes primarily related to revisions of variable consideration including award and incentive fees, and revisions to estimates at completion resulting from changes in contract scope, mitigation of contract risks or true-ups of contract estimates at the end of contract performance. Cash and Cash Equivalents Our cash equivalents are primarily comprised of investments in several large institutional money market accounts, with original maturity of three months or less. At September 29, 2023, and December 30, 2022, $64 million and $158 million, respectively, of outstanding payments were included within "Cash and cash equivalents" and "Accounts payable and accrued liabilities" correspondingly on the condensed consolidated balance sheets. Restricted Cash We have restricted cash balances, primarily representing advances from customers that are restricted for use on certain expenditures related to that customer's contract. Restricted cash balances are included as "Other current assets" in the condensed consolidated balance sheets. Our restricted cash balances were $189 million and $167 million at September 29, 2023, and December 30, 2022, respectively. |
Revenues
Revenues | 9 Months Ended |
Sep. 29, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Revenues | Note 2–Revenues Remaining Performance Obligations Remaining performance obligations ("RPO") represent the expected value of exercised contracts, both funded and unfunded, less revenue recognized to date. RPO does not include unexercised option periods and future potential task orders expected to be awarded under indefinite delivery/indefinite quantity ("IDIQ") contracts, General Services Administration Schedule or other master agreement contract vehicles, with the exception of certain IDIQ contracts where task orders are not competitively awarded and separately priced but instead are used as a funding mechanism, and where there is a basis for estimating future revenues and funding on future anticipated task orders. As of September 29, 2023, we had $15.5 billion of RPO and expect to recognize approximately 63% and 79% over the next 12 months and 24 months, respectively, with the remainder to be recognized thereafter. Disaggregation of Revenues We disaggregate revenues by customer-type, contract-type and geographic location for each of our reportable segments. Disaggregated revenues by customer-type were as follows: Three Months Ended September 29, 2023 Nine Months Ended September 29, 2023 Defense Solutions Civil Health Total Defense Solutions Civil Health Total (in millions) DoD and U.S. Intelligence Community $ 1,677 $ 28 $ 242 $ 1,947 $ 4,798 $ 71 $ 755 $ 5,624 Other U.S. government agencies (1) 261 695 512 1,468 772 2,054 1,413 4,239 Commercial and non-U.S. customers 283 177 22 482 948 512 66 1,526 Total $ 2,221 $ 900 $ 776 $ 3,897 $ 6,518 $ 2,637 $ 2,234 $ 11,389 Three Months Ended September 30, 2022 Nine Months Ended September 30, 2022 Defense Solutions Civil Health Total Defense Solutions Civil Health Total (in millions) DoD and U.S. Intelligence Community $ 1,559 $ 22 $ 255 $ 1,836 $ 4,620 $ 62 $ 732 $ 5,414 Other U.S. government agencies (1) 236 676 372 1,284 686 1,949 1,177 3,812 Commercial and non-U.S. customers 280 151 28 459 869 446 83 1,398 Total $ 2,075 $ 849 $ 655 $ 3,579 $ 6,175 $ 2,457 $ 1,992 $ 10,624 (1) Includes federal government agencies other than the DoD and U.S. Intelligence Community, as well as state and local government agencies. Disaggregated revenues by contract-type were as follows: Three Months Ended September 29, 2023 Nine Months Ended September 29, 2023 Defense Solutions Civil Health Total Defense Solutions Civil Health Total (in millions) Cost-reimbursement and fixed-price-incentive-fee $ 1,247 $ 472 $ 131 $ 1,850 $ 3,578 $ 1,401 $ 542 $ 5,521 Firm-fixed-price 718 286 543 1,547 2,128 813 1,396 4,337 Time-and-materials and fixed-price-level-of-effort 256 142 102 500 812 423 296 1,531 Total $ 2,221 $ 900 $ 776 $ 3,897 $ 6,518 $ 2,637 $ 2,234 $ 11,389 Three Months Ended September 30, 2022 Nine Months Ended September 30, 2022 Defense Solutions Civil Health Total Defense Solutions Civil Health Total (in millions) Cost-reimbursement and fixed-price-incentive-fee $ 1,166 $ 442 $ 200 $ 1,808 $ 3,493 $ 1,293 $ 534 $ 5,320 Firm-fixed-price 668 279 389 1,336 1,950 792 1,260 4,002 Time-and-materials and fixed-price-level-of-effort 241 128 66 435 732 372 198 1,302 Total $ 2,075 $ 849 $ 655 $ 3,579 $ 6,175 $ 2,457 $ 1,992 $ 10,624 Disaggregated revenues by geographic location were as follows: Three Months Ended September 29, 2023 Nine Months Ended September 29, 2023 Defense Solutions Civil Health Total Defense Solutions Civil Health Total (in millions) United States $ 1,936 $ 845 $ 776 $ 3,557 $ 5,659 $ 2,504 $ 2,234 $ 10,397 International 285 55 — 340 859 133 — 992 Total $ 2,221 $ 900 $ 776 $ 3,897 $ 6,518 $ 2,637 $ 2,234 $ 11,389 Three Months Ended September 30, 2022 Nine Months Ended September 30, 2022 Defense Solutions Civil Health Total Defense Solutions Civil Health Total (in millions) United States $ 1,830 $ 810 $ 655 $ 3,295 $ 5,429 $ 2,340 $ 1,992 $ 9,761 International 245 39 — 284 746 117 — 863 Total $ 2,075 $ 849 $ 655 $ 3,579 $ 6,175 $ 2,457 $ 1,992 $ 10,624 Revenues by customer-type, contract-type and geographic location exclude lease income of $24 million and $69 million for the three and nine months ended September 29, 2023, respectively, and $29 million and $75 million for the three and nine months ended September 30, 2022, respectively. Contract Assets and Liabilities Performance obligations are satisfied either over time as work progresses or at a point in time. Firm-fixed-price contracts are typically billed to the customer using milestone payments while cost-reimbursable and time and materials contracts are typically billed to the customer on a monthly or bi-weekly basis as indicated by the negotiated billing terms and conditions of the contract. As a result, the timing of revenue recognition, customer billings and cash collections for each contract results in a net contract asset or liability at the end of each reporting period. Contract assets consist of unbilled receivables, which is the amount of revenue recognized that exceeds the amount billed to the customer. Unbilled receivables exclude amounts billable where the right to consideration is solely subject to the passage of time. Contract liabilities consist of deferred revenue, which represents cash advances received prior to performance for programs and billings in excess of revenue recognized. The components of contract assets and contract liabilities consisted of the following: Balance sheet line item September 29, December 30, (in millions) Contract assets - current: Unbilled receivables Receivables, net $ 1,047 $ 1,010 Contract liabilities - current: Deferred revenue (1) Accounts payable and accrued liabilities $ 449 $ 380 Contract liabilities - non-current: Deferred revenue (1) Other long-term liabilities $ 23 $ 29 (1) Certain contracts record revenue net of cost of revenues, and therefore, the respective deferred revenue balance will not fully convert to revenue. Revenue recognized for the three and nine months ended September 29, 2023, of $28 million and $215 million, respectively, was included as a contract liability at December 30, 2022. Revenue recognized for the three and nine months ended September 30, 2022, of $17 million and $257 million, respectively, was included as a contract liability at December 31, 2021. |
Acquisitions, Divestitures, Goo
Acquisitions, Divestitures, Goodwill and Intangible Assets | 9 Months Ended |
Sep. 29, 2023 | |
Business Combination and Asset Acquisition [Abstract] | |
Acquisitions, Divestitures, Goodwill and Intangible Assets | Note 3–Acquisitions, Divestitures, Goodwill and Intangible Assets Business Acquisition On October 30, 2022 (the "Agreement Date"), we completed the acquisition of Cobham Special Mission for purchase consideration of $298 million Australian dollars, net of $10 million of Australian dollars acquired, or $192 million United States dollars, net of $6 million of cash acquired. Cobham Special Mission provides airborne border surveillance and search and rescue services to the Australian Federal Government. As of September 29, 2023, we completed the determination of fair values of the assets acquired and liabilities assumed.The final goodwill recognized of $22 million represents intellectual capital and the acquired assembled workforce, neither of which qualify for recognition as a separate intangible asset. None of the goodwill recognized is tax deductible. In connection with this acquisition, we acquired property, plant and equipment with a fair value of $148 million at the Agreement Date. The following table summarizes the fair value of intangible assets acquired at the Agreement Date and the related weighted average amortization period: Weighted average amortization period Fair value (in years) (in millions) Programs 11 $ 19 Technology 10 5 Total 11 $ 24 For the three and nine months ended September 29, 2023, $28 million and $86 million of revenues related to the Cobham Special Mission acquisition were recognized within the Defense Solutions reportable segmen t. Goodwill The following table presents changes in the carrying amount of goodwill by reportable segment: Defense Solutions Civil Health Total (in millions) Goodwill at December 31, 2021 (1) $ 3,681 $ 2,097 $ 966 $ 6,744 Acquisition of businesses 26 — — 26 Divestiture of a business (6) — — (6) Foreign currency translation adjustments (37) (31) — (68) Goodwill at December 30, 2022 (1) $ 3,664 $ 2,066 $ 966 $ 6,696 Goodwill impairment — (599) — (599) Acquisition of a business (2) (4) — — (4) Foreign currency translation adjustments (18) 4 — (14) Goodwill at September 29, 2023 (3) $ 3,642 $ 1,471 $ 966 $ 6,079 (1) Carrying amount includes accumulated impairment losses of $369 million and $117 million within the Health and Civil segments, respectively. (2) Adjustment to goodwill resulting from a measurement period purchase accounting adjustment. (3) Carrying amount includes accumulated impairment losses of $369 million and $716 million within the Health and Civil segments, respectively. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners or litigation. Operations of the Security Enterprise Solutions (“SES”) reporting unit rely heavily on the sales and servicing of security and detection products, which continue to be negatively impacted due to delays in airline travel infrastructure projects as customer budgetary restraints recover from reduced travel activity post-pandemic. During the third quarter of fiscal 2023, the SES reporting unit refined its portfolio and made strategic business decisions to exit certain product offerings, as well as cease operations in certain countries in order to align the operations of the reporting unit with its strategic business plan. These decisions, along with the delays in airline travel infrastructure projects and higher than anticipated servicing costs, contributed to a significant reduction in the reporting unit’s forecasted revenue and cash flows. As a result, we conducted an interim quantitative goodwill impairment analysis and our estimates led us to determine that the carrying value of the SES reporting unit exceeded its estimated fair value (see “Note 4–Fair Value Measurements”). Accordingly, we recognized a non-cash goodwill impairment charge of $599 million for the three and nine months ended September 29, 2023, leaving $303 million of goodwill at the SES reporting unit. The impairment was recorded within the Civil reportable segment in the condensed consolidated statements of operations. In the event that there are significant unfavorable changes to the forecasted cash flows, forecasted revenue, terminal growth rates or the cost of capital used in the fair value estimates, we may be required to record an additional impairment of goodwill at a future date. . Intangible Assets Intangible assets, net consisted of the following: September 29, 2023 December 30, 2022 Gross carrying value Accumulated amortization Net carrying value Gross carrying value Accumulated amortization Net carrying value (in millions) Finite-lived intangible assets: Programs $ 1,686 $ (1,132) $ 554 $ 1,721 $ (1,016) $ 705 Software and technology 203 (138) 65 225 (136) 89 Customer relationships 52 (21) 31 87 (25) 62 Trade names 1 (1) — 1 (1) — Total finite-lived intangible assets 1,942 (1,292) 650 2,034 (1,178) 856 Indefinite-lived intangible assets: In-process research and development ("IPR&D") (1) 59 — 59 92 — 92 Trade names 4 — 4 4 — 4 Total indefinite-lived intangible assets 63 — 63 96 — 96 Total intangible assets $ 2,005 $ (1,292) $ 713 $ 2,130 $ (1,178) $ 952 (1) IPR&D assets are indefinite-lived at the acquisition date until placed into service, at which time such assets will be reclassified to a finite-lived amortizable intangible asset. Our strategic decisions regarding SES’ product offerings and operating regions (see the goodwill discussion on page 13) caused certain technology and IPR&D intangible assets to be abandoned and the carrying values of certain program intangible assets to become unrecoverable. As a result, for the three and nine months ended September 29, 2023, we recognized intangible asset impairment charges of $79 million. The impairment was recorded to “Asset impairment charges” in the condensed consolidated statements of operations within the Civil reportable segment. In the event that we are required to make an additional impairment of goodwill at a future date for any of the reasons identified in our discussion of goodwill or if other events occur that negatively impact these intangible assets, we may also be required to record an additional impairment of intangible assets at that time. Amortization expense was $50 million and $153 million for the three and nine months ended September 29, 2023, respectively and $57 million and $173 million for the three and nine months ended September 30, 2022, respectively. Program intangible assets are amortized over their respective estimated useful lives in proportion to the pattern of economic benefit based on expected future discounted cash flows. Backlog and finite-lived trade name intangible assets are amortized on a straight-line basis over their estimated useful lives. Customer relationships and software and technology intangible assets are amortized either on a straight-line basis over their estimated useful lives or over their respective estimated useful lives in proportion to the pattern of economic benefit based on expected future discounted cash flows, as deemed appropriate. The estimated annual amortization expense as of September 29, 2023, was as follows: Fiscal year ending (in millions) 2023 (remainder of year) $ 49 2024 140 2025 113 2026 92 2027 66 2028 and thereafter 190 $ 650 |
Fair Value Measurements
Fair Value Measurements | 9 Months Ended |
Sep. 29, 2023 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Note 4–Fair Value Measurements The accounting standard for fair value measurements establishes a three-level fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: observable inputs such as quoted prices in active markets (Level 1); inputs other than quoted prices in active markets that are observable, either directly or indirectly, or quoted prices that are not active (Level 2); and unobservable inputs in which there is little or no market data (e.g., discounted cash flow and other similar pricing models), which requires us to develop our own market participant assumptions used in pricing the asset or liability (Level 3). The financial instruments measured at fair value on a recurring basis primarily consisted of the following: September 29, 2023 December 30, 2022 Carrying value Fair value Carrying value Fair value (in millions) Financial assets: Derivatives $ 19 $ 19 $ 20 $ 20 As of September 29, 2023, and December 30, 2022, our derivatives primarily consisted of the cash flow interest rate swaps on $500 million and $1.0 billion, respectively, of the variable rate senior unsecured term loan (see "Note 5–Derivative Instruments"). The fair value of the cash flow interest rate swaps is determined based on observed values for underlying interest rates on the one-month SOFR rate as of September 29, 2023 and the LIBOR yield curve as of December 30, 2022 (Level 2 inputs). The carrying amounts of our financial instruments, other than derivatives, which include cash equivalents, accounts receivable, accounts payable and accrued expenses, are reasonable estimates of their related fair values. As of September 29, 2023, and December 30, 2022, the fair value of debt was $4.3 billion and $4.6 billion, respectively, and the carrying amount was $4.7 billion and $4.9 billion, respectively (see "Note 6–Debt"). The fair value of long-term debt is determined based on current interest rates available for debt with terms and maturities similar to our existing debt arrangements (Level 2 inputs). During the three months ended September 29, 2023, we recorded impairment charges of SES' goodwill (see "Note 3–Acquisitions, Divestitures, Goodwill and Intangible Assets"). The fair values of the assets and liabilities of the SES reporting unit were determined using a blended approach, including discounted cash flow models and market earnings multiples. The market approach estimates fair value based on profitability and valuation metrics for peer companies and applies a multiple to the reporting unit's operating performance. The income approach estimates fair value by discounting the reporting unit's estimated future cash flows using a weighted-average cost of capital reflecting current market conditions as well as the risk profile of the reporting unit. Future cash flows are based on estimates of economic and market assumptions made using the best judgment of management, including growth rates in revenue and margins, and future changes in tax rates and cash expenditures. Other significant assumptions and estimates include estimates of future capital expenditures, terminal value growth rates, and changes in future working capital requirements. The fair value of the SES reporting unit was determined using Level 3 inputs. |
Derivative Instruments
Derivative Instruments | 9 Months Ended |
Sep. 29, 2023 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivative Instruments | Note 5–Derivative Instruments We manage our risk to changes in interest rates through the use of derivative instruments. We do not hold derivative instruments for trading or speculative purposes. For variable rate borrowings, we use fixed interest rate swaps, effectively converting a portion of the variable interest rate payments to fixed interest rate payments. These swaps are designated as cash flow hedges. The fair value of the interest rate swaps was as follows: Asset derivatives Balance sheet line item September 29, December 30, (in millions) Cash flow interest rate swaps Other long-term assets $ 19 $ 20 The cash flows associated with the interest rate swaps are classified as operating activities in the condensed consolidated statements of cash flows. Cash Flow Hedges We have interest rate swap agreements to hedge the cash flows of $500 million of the variable rate senior unsecured term loan (the "Variable Rate Loan"). These interest rate swap agreements have a maturity date of August 2025 and a fixed interest rate of 2.96%. The objective of these instruments is to reduce variability in the forecasted interest payments of the Variable Rate Loan. During fiscal 2023, we modified our interest rate swap agreements to receive monthly variable interest payments based on the one-month SOFR rate, as compared to LIBOR, and will continue to pay interest at a fixed rate. We applied the guidance of ASC 848 which permits the continuation of hedge accounting for such modification. The interest rate swap transactions are accounted for as cash flow hedges. The gain/loss on the swaps is reported as a component of other comprehensive (loss) income and is reclassified into earnings when the interest payments on the underlying hedged items impact earnings. A qualitative assessment of hedge effectiveness is performed on a quarterly basis, unless facts and circumstances indicate the hedge may no longer be highly effective. The effect of the cash flow hedges on other comprehensive income (loss) and earnings for the periods presented was as follows: Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (in millions) Total interest expense, net presented in the condensed consolidated statements of operations in which the effects of cash flow hedges are recorded $ 53 $ 50 $ 163 $ 148 Amount recognized in other comprehensive income (loss) $ 3 $ 21 $ 11 $ 57 Amount reclassified from accumulated other comprehensive income (loss) to interest expense, net $ (3) $ 2 $ (12) $ 13 We expect to reclassify net gains of $13 million from accumulated other comprehensive loss into earnings during the next 12 months. |
Debt
Debt | 9 Months Ended |
Sep. 29, 2023 | |
Debt Disclosure [Abstract] | |
Debt | Note 6–Debt Our debt consisted of the following: Stated interest rate Effective interest rate September 29, December 30, 2022 (in millions) Short-term debt and current portion of long-term debt: Senior unsecured term loans: $380 million term loan, due May 2023 6.08% 6.17% $ — $ 320 Current portion of long-term debt 18 672 Total short-term debt and current portion of long-term debt $ 18 $ 992 Long-term debt: Senior unsecured term loans: $1,925 million term loan, due January 2025 5.77% 6.09% $ — $ 1,211 $1,000 million term loan, due March 2028 6.68% 6.86% 1,000 — Senior unsecured notes: $500 million notes, due May 2023 2.95% 3.17% — 500 $500 million notes, due May 2025 3.63% 3.76% 500 500 $750 million notes due May 2030 4.38% 4.50% 750 750 $750 million notes due March 2033 5.75% 5.81% 750 — $1,000 million notes, due February 2031 2.30% 2.38% 1,000 1,000 $250 million notes, due July 2032 7.13% 7.43% 250 250 $300 million notes, due July 2033 5.50% 5.88% 161 161 $300 million notes, due December 2040 5.95% 6.03% 218 218 Finance leases due on various dates through fiscal 2032 Various 1.84%-6.31% 96 44 Less: unamortized debt discounts and deferred debt issuance costs (40) (34) Total long-term debt 4,685 4,600 Less current portion (18) (672) Total long-term debt, net of current portion $ 4,667 $ 3,928 Term Loans and Revolving Credit Facility On March 10, 2023 (the “Closing Date”), we entered into a Credit Agreement (the “Credit Agreement”) with certain financial institutions, which provided for a senior unsecured term loan facility in an aggregate principal amount of $1.0 billion (the “Term Loan Facility”) and a $1.0 billion senior unsecured revolving facility (the “Revolving Facility” and, together with the Term Loan Facility, the “Credit Facilities”). The Credit Facilities will mature in March 2028. The Revolving Facility permits two additional one-year extensions subject to lender consent. As of September 29, 2023, there were no borrowings outstanding under the Revolving Facility. The proceeds of the Term Loan Facility and cash on hand on the Closing Date were used to repay in full all indebtedness, terminate all commitments and discharge all guarantees existing in connection with the credit agreement related to the $1.9 billion senior unsecured term loan facility and $750 million senior unsecured revolving facility. Borrowings under the Credit Agreement bear interest at a rate determined, at our option, based on either an alternate base rate or a Term SOFR rate with a 0.10% per annum Term SOFR adjustment, plus, in each case, an applicable margin that varies depending on our credit rating. The applicable margin range for Term SOFR-denominated borrowings is from 1.00% to 1.50%. Based on our current ratings, the applicable margin for Term SOFR-denominated borrowings is 1.25%. Principal payments are made quarterly on the Term Loan Facility beginning in March 2025, with the majority of the principal due at maturity. Interest on the Term Loan Facility for Term SOFR-denominated borrowings is payable on a periodic basis, which must be at least quarterly. The financial covenants in the Credit Agreement require that we maintain, as of the last day of each fiscal quarter, a ratio of adjusted consolidated total debt to consolidated EBITDA of not more than 3.75 to 1.00, subject to two increases to 4.50 to 1.00 for four fiscal quarters following a material acquisition, and a ratio of EBITDA to consolidated interest expense of not less than 3.50 to 1.00. Senior Notes On February 28, 2023, we issued and sold $750 million aggregate principal amount of fixed-rate senior notes (the “Notes”) maturing in March 2033. The Notes are senior unsecured obligations issued by Leidos, Inc. and guaranteed by Leidos Holdings, Inc. The annual interest rate for the Notes is 5.75% and is payable on a semi-annual basis. In connection with the issuance of the Notes, $11 million of debt issuance costs and discount were recognized, which were recorded as an offset against the carrying value of debt. The proceeds from the Notes were used to repay all of the outstanding obligations in respect of principal, interest and fees on the $500 million 2.95% notes, due May 2023, the majority of which were retired on February 28, 2023. The remaining proceeds from the Notes were used to repay $210 million of the outstanding balance on the $1.9 billion senior unsecured term loan facility, due January 2025, and fund general corporate purposes. Commercial Paper We have a commercial paper program in which the Company may issue short-term unsecured commercial paper notes ("Commercial Paper Notes"). On May 26, 2023, we increased the size of the commercial paper program by $250 million, or not to exceed $1.0 billion. The proceeds will be used for general corporate purposes, including working capital, capital expenditures, acquisitions and share repurchases. The Commercial Paper Notes are issued in minimum denominations of $0.25 million and have maturities of up to 397 days from the date of issuance. The Commercial Paper Notes either bear a stated or floating interest rate, if interest bearing, or will be sold at a discount from the face amount. As of September 29, 2023, we did not have any Commercial Paper Notes outstanding. The Credit Facilities, Commercial Paper Notes, senior unsecured term loans and notes are fully and unconditionally guaranteed and contain certain customary restrictive covenants, including among other things, restrictions on our ability to create liens and enter into sale and leaseback transactions under certain circumstances. We were in compliance with all covenants as of September 29, 2023. Finance Leases In fiscal 2022, the Company entered into a Master Lease Agreement whereby we agreed to lease two aircraft from the time each aircraft is accepted through June 30, 2027. In March 2023, we took possession of both aircraft and recognized a $64 million finance lease obligation and a corresponding property, plant and equipment asset. Principal Payments Future minimum payments of debt are as follows: Fiscal year ending (in millions) 2023 (remainder of year) $ 5 2024 18 2025 619 2026 120 2027 114 2028 and thereafter 3,849 Total principal payments 4,725 Less: unamortized debt discounts and deferred debt issuance costs (40) Total short-term and long-term debt $ 4,685 |
Accumulated Other Comprehensive
Accumulated Other Comprehensive Income (Loss) | 9 Months Ended |
Sep. 29, 2023 | |
Equity [Abstract] | |
Accumulated Other Comprehensive Income (Loss) | Note 7–Accumulated Other Comprehensive Income (Loss) Changes in the components of Accumulated Other Comprehensive Income (Loss) ("AOCI") were as follows: Foreign currency translation adjustments Unrecognized gain (loss) on derivative instruments Pension adjustments Total AOCI (in millions) Balance at December 31, 2021 $ 22 $ (41) $ 7 $ (12) Other comprehensive income (loss) (108) 59 (27) (76) Taxes 13 (16) 7 4 Reclassification from AOCI — 11 — 11 Balance at December 30, 2022 (73) 13 (13) (73) Other comprehensive income (loss) (22) 11 (1) (12) Taxes 3 — (1) 2 Reclassification from AOCI — (12) — (12) Balance at September 29, 2023 $ (92) $ 12 $ (15) $ (95) Reclassifications from unrecognized gain (loss) on derivative instruments are recorded in "Interest expense, net" in the condensed consolidated statements of operations. |
Earnings Per Share
Earnings Per Share | 9 Months Ended |
Sep. 29, 2023 | |
Earnings Per Share [Abstract] | |
Earnings Per Share | Note 8–Earnings Per Share The following table provides a reconciliation of the weighted average number of shares outstanding used to compute basic and diluted EPS for the periods presented: Three Months Ended Nine Months Ended September 29, 2023 (1) September 30, September 29, 2023 (1) September 30, (in millions) Basic weighted average number of shares outstanding 137 137 137 137 Dilutive common share equivalents—stock options and other stock awards — 1 — 1 Diluted weighted average number of shares outstanding 137 138 137 138 (1) Dilutive common share equivalents did not include the impact of 1 million potentially dilutive equity awards because the result would have been anti-dilutive due to the net losses. Anti-dilutive stock-based awards are excluded from the weighted average number of shares outstanding used to compute diluted EPS. For the three and nine months ended September 29, 2023, and September 30, 2022, the total outstanding stock options and vesting stock awards that were anti-dilutive were 2 million and 1 million, respectively. During the nine months ended September 29, 2023, we made open market repurchases of our common stock for an aggregate purchase price of $25 million. All shares repurchased were immediately retired. No share repurchases were made under the Company’s share repurchase program during the three months ended September 29, 2023. |
Income Taxes
Income Taxes | 9 Months Ended |
Sep. 29, 2023 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Note 9–Income Taxes For the three months ended September 29, 2023, the effective tax rate was (2.1)% compared to 25.8% for the three months ended September 30, 2022. The decrease to the effective tax rate was primarily due to the tax impacts of non-deductible goodwill impairments, see "Note 3–Acquisitions, Divestitures, Goodwill and Intangible Assets" for further information. For the nine months ended September 29, 2023, the effective tax rate was 123.7% compared to 23.2% for the nine months ended September 30, 2022. The increase to the effective tax rate was primarily due to the tax impacts of non-deductible goodwill impairments, see "Note 3–Acquisitions, Divestitures, Goodwill and Intangible Assets" for further information. Beginning in 2022, the Tax Cuts and Jobs Act of 2017 (“TCJA”) eliminated the option to currently deduct certain research and development costs for tax purposes and requires taxpayers to capitalize and amortize research costs over five years. TCJA increased both our income taxes payable and net deferred tax assets since the beginning of 2022. For the nine months ended September 29, 2023, unrecognized tax benefits increased $71 million with a corresponding increase to net deferred tax assets as a result of uncertain tax positions arising from capitalizing research and development costs. Future impacts of TCJA will depend on the amount of research and development costs the Company will incur, whether Congress modifies or repeals this provision and whether new guidance and interpretive rules are issued by the U.S. Treasury, among other factors. |
Business Segments
Business Segments | 9 Months Ended |
Sep. 29, 2023 | |
Segment Reporting [Abstract] | |
Business Segments | Note 10–Business Segments Our operations and reportable segments are organized around the customers and markets we serve. We define our reportable segments based on the way the chief operating decision maker ("CODM"), currently our Chief Executive Officer, manages operations for the purposes of allocating resources and assessing performance. The segment information for the periods presented was as follows: Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (in millions) Revenues: Defense Solutions $ 2,221 $ 2,075 $ 6,520 $ 6,176 Civil 924 874 2,703 2,526 Health 776 659 2,235 1,997 Total revenues $ 3,921 $ 3,608 $ 11,458 $ 10,699 Operating (loss) income: Defense Solutions $ 147 $ 137 $ 469 $ 409 Civil (607) 79 (503) 160 Health 152 91 381 335 Corporate (28) (26) (87) (81) Total operating (loss) income $ (336) $ 281 $ 260 $ 823 |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Sep. 29, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Note 11–Commitments and Contingencies Contingencies VirnetX, Inc. ("VirnetX") On April 10, 2018, a jury trial concluded in an additional patent infringement case brought by VirnetX against Apple, referred to as the Apple II case, in which the jury returned a verdict against Apple for infringement and awarded VirnetX damages in the amount of over $502 million. On April 11, 2018, in a second phase of the Apple II trial, the jury found Apple's infringement to be willful. On August 30, 2018, the federal trial court in the Eastern District of Texas entered a final judgment and rulings on post-trial motions in the Apple II case. The court affirmed the jury’s verdict of over $502 million and granted VirnetX’s motions for supplemental damages, a sunset royalty and royalty rate of $1.20 per infringing device, along with pre-judgment and post-judgment interest and costs. The court denied VirnetX’s motions for enhanced damages, attorneys’ fees and an injunction. The court also denied Apple’s motions for judgment as a matter of law and for a new trial. An additional sum of over $93 million for costs and pre-judgment interest was subsequently agreed upon pursuant to a court order, bringing the total award to VirnetX in the Apple II case to over $595 million. Apple filed an appeal of the judgment in the Apple II case with the U.S. Court of Appeals for the Federal Circuit, and on November 22, 2019, the Federal Circuit affirmed in part, reversed in part and remanded the Apple II case back to the District Court. The Federal Circuit affirmed that Apple infringed two of the patents at issue in the case, and ruled that Apple is precluded from making certain patent invalidity arguments. However, the Federal Circuit reversed the judgment that Apple infringed two other patents at issue, vacated the prior damages awarded in the Apple II case, and remanded the Apple II case back to the District Court for further proceedings regarding damages. On April 23, 2020, the District Court ordered a new trial on damages in the Apple II case, which was delayed by the coronavirus pandemic and started on October 26, 2020. On October 30, 2020, the jury awarded VirnetX $503 million in damages and specified a royalty rate of $0.84 per infringing device. In January 2021, the District Court entered final judgment affirming the jury award and the parties separately agreed on additional costs and interest of over $75 million, subject to Apple's appeal. On February 4, 2021, Apple filed a notice of appeal with the U.S. Court of Appeals for the Federal Circuit in the Apple II case. Under our agreements with VirnetX, Leidos would receive 25% of the proceeds obtained by VirnetX after reduction for attorneys' fees and costs. However, the verdict in the Apple II case remains subject to the ongoing and potential future proceedings and appeals. In addition, the patents at issue in these cases are subject to U.S. Patent and Trademark Office ("USPTO") post-grant inter partes review and/or reexamination proceedings and related appeals, which may result in all or part of these patents being invalidated or the claims of the patents being limited. On March 30, 2023, the U.S. Court of Appeals for the Federal Circuit issued a ruling affirming prior decisions of the USPTO’s Patent Trial and Appeal Board finding certain claims of the patents at issue in the Apple II case to be unpatentable. On March 31, 2023, the Federal Circuit issued a decision vacating the District Court’s judgment in the Apple II case and remanding it back to the District Court with instructions to dismiss the case as moot. These Federal Circuit decisions remain subject to potential motions and/or appeals by VirnetX, including potentially seeking rehearing or certiorari review. On May 1, 2023, VirnetX filed a petition for panel rehearing on the Apple II litigation decision at the Federal Circuit, but this petition was denied by the Federal Circuit on June 27, 2023. On June 5, 2023, VirnetX filed a petition for panel rehearing on the Federal Circuit’s decision finding the patents at issue in the Apple II case to be unpatentable, but this petition was denied by the Federal Circuit on June 22, 2023. On September 20, 2023, VirnetX filed a petition for a writ of certiorari with the Supreme Court of the United States to review the Federal Circuit decisions. Thus, no assurances can be given when or if we will receive any proceeds in connection with the Apple II case. In addition, if Leidos receives any proceeds, we are required to pay a royalty to the customer who paid for the development of the technology. Government Investigations and Reviews We are routinely subject to investigations and reviews relating to compliance with various laws and regulations with respect to our role as a contractor to federal, state and local government customers and in connection with performing services in countries outside of the United States. Adverse findings could have a material effect on our business, financial position, results of operations and cash flows due to our reliance on government contracts. Defense Contract Audit Agency As of September 29, 2023, active indirect cost audits by the Defense Contract Audit Agency remain open for fiscal 2021 and subsequent fiscal years. Although we have recorded contract revenues based upon an estimate of costs that we believe will be approved upon final audit or review, we cannot predict the outcome of any ongoing or future audits or reviews and adjustments, and if future adjustments exceed estimates, our profitability may be adversely affected. As of September 29, 2023, we believe we have adequately reserved for potential adjustments from audits or reviews of contract costs. Other Government Investigations and Reviews Through its internal processes, the Company discovered, in late 2021, activities by its employees, third party representatives and subcontractors, raising concerns related to a portion of our business that conducts international operations. The Company is conducting an internal investigation, overseen by an independent committee of the Board of Directors, with the assistance of external legal counsel, to determine whether the identified conduct may have violated the Company’s Code of Conduct and potentially applicable laws, including the U.S. Foreign Corrupt Practices Act ("FCPA"). The Company has voluntarily self-reported this investigation to the Department of Justice and the Securities and Exchange Commission and is cooperating with both agencies. Because the investigation is ongoing, the Company cannot anticipate the timing, outcome or possible impact of the investigation, although violations of the FCPA and other applicable laws may result in criminal and civil sanctions, including monetary penalties, and reputational damage. In September 2022, the Company received a Federal Grand Jury Subpoena related to the criminal investigation by the U.S. Attorney’s Office for the Southern District of California, in conjunction with the U.S. Department of Justice’s Fraud Division. The subpoena requests documents relating to the conduct that is the subject of the Company’s internal investigation. The Company has responded to the subpoena. In February 2023, a former employee of the Company who was terminated at the outset of the investigation was indicted on wire fraud and other charges by a Federal Grand Jury in the U.S. District Court in the Southern District of California. In August 2022, the Company received a Federal Grand Jury Subpoena in connection with a criminal investigation being conducted by the U.S. Department of Justice Antitrust Division. The subpoena requests that the Company produce a broad range of documents related to three U.S. Government procurements associated with the Company’s Intelligence Group in 2021 and 2022. We are fully cooperating with the investigation, and we are conducting our own internal investigation with the assistance of outside counsel. It is not possible at this time to determine whether we will incur, or to reasonably estimate the amount of, any fines, penalties, or further liabilities in connection with the investigation pursuant to which the subpoena was issued. Commitments As of September 29, 2023, we have outstanding letters of credit of $60 million , principally related to performance guarantees on contracts and outstanding surety bonds with a notional amount of $104 million , principally related to performance and subcontractor payment bonds on contracts. The value of the surety bonds may vary due to changes in the underlying project status and/or contractual modifications. As of September 29, 2023, the future expirations of the outstanding letters of credit and surety bonds were as follows: Fiscal year ending (in millions) 2023 (remainder of year) $ 34 2024 10 2025 102 2026 2 2027 13 2028 and thereafter 3 $ 164 |
Pay vs Performance Disclosure
Pay vs Performance Disclosure - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 29, 2023 | Sep. 30, 2022 | Sep. 29, 2023 | Sep. 30, 2022 | |
Pay vs Performance Disclosure | ||||
Net Income (Loss) | $ (399) | $ 162 | $ (30) | $ 508 |
Insider Trading Arrangements
Insider Trading Arrangements | 3 Months Ended | 9 Months Ended |
Sep. 29, 2023 shares | Sep. 29, 2023 shares | |
Trading Arrangements, by Individual | ||
Material Terms of Trading Arrangement | The following table includes the material terms of each trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1 (c) under the Securities Exchange Act of 1934, as amended ("Rule 10b5-1 Plan") by our executive officers and directors during the three months ended September 29, 2023: Name and title Date of adoption (1) Date of termination Scheduled expiration date (2) Aggregate number of shares of common stock to be purchased or sold (3) James R. Moos, President - Civil August 3, 2023 N/A March 2, 2024 Up to 2,134 shares underlying options expiring March 2, 2024 (1) Transactions under each Rule 10b5-1 Plan commence no earlier than 90 days after adoption, or such later date as required by Rule 10b5-1. (2) Each Rule 10b5-1 Plan may expire on such earlier date as all transactions are completed. (3) Each Rule 10b5-1 Plan provides for shares to be sold on multiple predetermined dates. | |
James R. Moos [Member] | ||
Trading Arrangements, by Individual | ||
Name | James R. Moos | |
Title | President - Civil | |
Rule 10b5-1 Arrangement Adopted | true | |
Adoption Date | August 3, 2023 | |
Arrangement Duration | 212 days | |
Aggregate Available | 2,134 | 2,134 |
Basis of Presentation and Sum_2
Basis of Presentation and Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 29, 2023 | |
Accounting Policies [Abstract] | |
Consolidation | We have a controlling interest in Mission Support Alliance, LLC ("MSA"), a joint venture with Centerra Group, LLC. We also have a controlling interest in Hanford Mission Integration Solutions, LLC ("HMIS"), the legal entity for the follow-on contract to MSA's contract and a joint venture with Centerra Group, LLC and Parsons Government Services, Inc. The financial results for MSA and HMIS are consolidated into our unaudited condensed consolidated financial statements. The unaudited condensed consolidated financial statements also include the balances of all voting interest entities in which Leidos has a controlling voting interest ("subsidiaries") and a variable interest entity ("VIE") in which Leidos is the primary beneficiary. The consolidated balances of the VIE are not material to the unaudited condensed consolidated financial statements for the periods presented. Intercompany accounts and transactions between consolidated companies have been eliminated in consolidation. |
Basis of Accounting | The accompanying unaudited condensed consolidated financial statements has been prepared in accordance with the rules of the U.S. Securities and Exchange Commission and accounting principles generally accepted in the United States of America ("GAAP"). Certain disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules. |
Estimates | The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. Management evaluates these estimates and assumptions on an ongoing basis, including those relating to estimated profitability of long-term contracts, indirect billing rates, allowances for doubtful accounts, inventories, right-of-use assets and lease liabilities, fair value and impairment of intangible assets and goodwill, income taxes, stock-based compensation expense and contingencies. These estimates have been prepared by management on the basis of the most current and best available information; however, actual results could differ materially from those estimates. |
Accounting Standards Updates Issued and Adopted | Accounting Standards Updates Issued and Adopted ASU 2020-04, ASU 2021-01 and ASU 2022-06, Reference Rate Reform (ASC 848) In March 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-04, which provides companies with optional expedients and exceptions to ease the potential accounting burden associated with transitioning away from reference rates that are expected to be discontinued. This update provides optional expedients for applying accounting guidance to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of the reference rate reform. The amendments in this update are effective for all entities as of March 2020 and can be adopted using a prospective approach no later than December 31, 2022. In January 2021, the FASB issued ASU 2021-01 which amends the scope of ASU 2020-04. The amendments in this update are elective and provide optional relief for entities with hedge accounting and contract modifications affected by the transition from LIBOR through December 31, 2022. In December 2022, the FASB issued ASU 2022-06 which extends the deadline for application of ASU 2021-01 through December 31, 2024. Under this relief, entities may continue to account for contract modifications as a continuation of the existing contract and the continuation of the hedge accounting arrangement. In the first half of fiscal 2023, we adopted certain practical expedients available under ASC 848. Our term loans are based on a Secured Overnight Financing Rate (“SOFR”) rate (see "Note 6–Debt"). Additionally, we modified our interest rate swap agreements to reference SOFR (see "Note 5–Derivative Instruments") in conformity with the relief available under ASC 848. The standard did not have a material impact on our financial position, results of operations or earnings per share. |
Changes in Estimates on Contracts | Changes in Estimates on Contracts Changes in estimates related to contracts accounted for using the cost-to-cost method of accounting are recognized in the period in which such changes are made for the inception-to-date effect of the changes, with the exception of contracts acquired through a business combination, where the adjustment is made for the period commencing from the date of acquisition.The impact on diluted earnings per share ("EPS") attributable to Leidos common stockholders is calculated using the statutory tax rate.The changes primarily related to revisions of variable consideration including award and incentive fees, and revisions to estimates at completion resulting from changes in contract scope, mitigation of contract risks or true-ups of contract estimates at the end of contract performance. |
Cash and Cash Equivalents | Cash and Cash EquivalentsOur cash equivalents are primarily comprised of investments in several large institutional money market accounts, with original maturity of three months or less.outstanding payments were included within "Cash and cash equivalents" and "Accounts payable and accrued liabilities" correspondingly on the condensed consolidated balance sheets. |
Restricted Cash | Restricted CashWe have restricted cash balances, primarily representing advances from customers that are restricted for use on certain expenditures related to that customer's contract. Restricted cash balances are included as "Other current assets" in the condensed consolidated balance sheets. |
Basis of Presentation and Sum_3
Basis of Presentation and Summary of Significant Accounting Policies (Tables) | 9 Months Ended |
Sep. 29, 2023 | |
Accounting Policies [Abstract] | |
Schedule of Changes in Estimates on Contracts | Changes in estimates on contracts were as follows: Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (in millions, except per share data) Favorable impact $ 40 $ 36 $ 102 $ 116 Unfavorable impact (24) (29) (62) (75) Net impact to (loss) income before income taxes $ 16 $ 7 $ 40 $ 41 Impact on diluted EPS attributable to Leidos common stockholders $ 0.09 $ 0.03 $ 0.22 $ 0.22 |
Revenues (Tables)
Revenues (Tables) | 9 Months Ended |
Sep. 29, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Schedule of Disaggregated Revenues | Disaggregated revenues by customer-type were as follows: Three Months Ended September 29, 2023 Nine Months Ended September 29, 2023 Defense Solutions Civil Health Total Defense Solutions Civil Health Total (in millions) DoD and U.S. Intelligence Community $ 1,677 $ 28 $ 242 $ 1,947 $ 4,798 $ 71 $ 755 $ 5,624 Other U.S. government agencies (1) 261 695 512 1,468 772 2,054 1,413 4,239 Commercial and non-U.S. customers 283 177 22 482 948 512 66 1,526 Total $ 2,221 $ 900 $ 776 $ 3,897 $ 6,518 $ 2,637 $ 2,234 $ 11,389 Three Months Ended September 30, 2022 Nine Months Ended September 30, 2022 Defense Solutions Civil Health Total Defense Solutions Civil Health Total (in millions) DoD and U.S. Intelligence Community $ 1,559 $ 22 $ 255 $ 1,836 $ 4,620 $ 62 $ 732 $ 5,414 Other U.S. government agencies (1) 236 676 372 1,284 686 1,949 1,177 3,812 Commercial and non-U.S. customers 280 151 28 459 869 446 83 1,398 Total $ 2,075 $ 849 $ 655 $ 3,579 $ 6,175 $ 2,457 $ 1,992 $ 10,624 (1) Includes federal government agencies other than the DoD and U.S. Intelligence Community, as well as state and local government agencies. Disaggregated revenues by contract-type were as follows: Three Months Ended September 29, 2023 Nine Months Ended September 29, 2023 Defense Solutions Civil Health Total Defense Solutions Civil Health Total (in millions) Cost-reimbursement and fixed-price-incentive-fee $ 1,247 $ 472 $ 131 $ 1,850 $ 3,578 $ 1,401 $ 542 $ 5,521 Firm-fixed-price 718 286 543 1,547 2,128 813 1,396 4,337 Time-and-materials and fixed-price-level-of-effort 256 142 102 500 812 423 296 1,531 Total $ 2,221 $ 900 $ 776 $ 3,897 $ 6,518 $ 2,637 $ 2,234 $ 11,389 Three Months Ended September 30, 2022 Nine Months Ended September 30, 2022 Defense Solutions Civil Health Total Defense Solutions Civil Health Total (in millions) Cost-reimbursement and fixed-price-incentive-fee $ 1,166 $ 442 $ 200 $ 1,808 $ 3,493 $ 1,293 $ 534 $ 5,320 Firm-fixed-price 668 279 389 1,336 1,950 792 1,260 4,002 Time-and-materials and fixed-price-level-of-effort 241 128 66 435 732 372 198 1,302 Total $ 2,075 $ 849 $ 655 $ 3,579 $ 6,175 $ 2,457 $ 1,992 $ 10,624 Disaggregated revenues by geographic location were as follows: Three Months Ended September 29, 2023 Nine Months Ended September 29, 2023 Defense Solutions Civil Health Total Defense Solutions Civil Health Total (in millions) United States $ 1,936 $ 845 $ 776 $ 3,557 $ 5,659 $ 2,504 $ 2,234 $ 10,397 International 285 55 — 340 859 133 — 992 Total $ 2,221 $ 900 $ 776 $ 3,897 $ 6,518 $ 2,637 $ 2,234 $ 11,389 Three Months Ended September 30, 2022 Nine Months Ended September 30, 2022 Defense Solutions Civil Health Total Defense Solutions Civil Health Total (in millions) United States $ 1,830 $ 810 $ 655 $ 3,295 $ 5,429 $ 2,340 $ 1,992 $ 9,761 International 245 39 — 284 746 117 — 863 Total $ 2,075 $ 849 $ 655 $ 3,579 $ 6,175 $ 2,457 $ 1,992 $ 10,624 |
Schedule of Components of Contract Assets and Contract Liabilities | The components of contract assets and contract liabilities consisted of the following: Balance sheet line item September 29, December 30, (in millions) Contract assets - current: Unbilled receivables Receivables, net $ 1,047 $ 1,010 Contract liabilities - current: Deferred revenue (1) Accounts payable and accrued liabilities $ 449 $ 380 Contract liabilities - non-current: Deferred revenue (1) Other long-term liabilities $ 23 $ 29 (1) Certain contracts record revenue net of cost of revenues, and therefore, the respective deferred revenue balance will not fully convert to revenue. |
Acquisitions, Divestitures, G_2
Acquisitions, Divestitures, Goodwill and Intangible Assets (Tables) | 9 Months Ended |
Sep. 29, 2023 | |
Business Combination and Asset Acquisition [Abstract] | |
Schedule of Preliminary Fair Values of Intangible Assets Acquired and Related Weighted Average Amortization Periods | The following table summarizes the fair value of intangible assets acquired at the Agreement Date and the related weighted average amortization period: Weighted average amortization period Fair value (in years) (in millions) Programs 11 $ 19 Technology 10 5 Total 11 $ 24 |
Schedule of Carrying Amount of Goodwill by Reportable Segment | The following table presents changes in the carrying amount of goodwill by reportable segment: Defense Solutions Civil Health Total (in millions) Goodwill at December 31, 2021 (1) $ 3,681 $ 2,097 $ 966 $ 6,744 Acquisition of businesses 26 — — 26 Divestiture of a business (6) — — (6) Foreign currency translation adjustments (37) (31) — (68) Goodwill at December 30, 2022 (1) $ 3,664 $ 2,066 $ 966 $ 6,696 Goodwill impairment — (599) — (599) Acquisition of a business (2) (4) — — (4) Foreign currency translation adjustments (18) 4 — (14) Goodwill at September 29, 2023 (3) $ 3,642 $ 1,471 $ 966 $ 6,079 (1) Carrying amount includes accumulated impairment losses of $369 million and $117 million within the Health and Civil segments, respectively. (2) Adjustment to goodwill resulting from a measurement period purchase accounting adjustment. (3) Carrying amount includes accumulated impairment losses of $369 million and $716 million within the Health and Civil segments, respectively. |
Schedule of Intangible Assets | Intangible assets, net consisted of the following: September 29, 2023 December 30, 2022 Gross carrying value Accumulated amortization Net carrying value Gross carrying value Accumulated amortization Net carrying value (in millions) Finite-lived intangible assets: Programs $ 1,686 $ (1,132) $ 554 $ 1,721 $ (1,016) $ 705 Software and technology 203 (138) 65 225 (136) 89 Customer relationships 52 (21) 31 87 (25) 62 Trade names 1 (1) — 1 (1) — Total finite-lived intangible assets 1,942 (1,292) 650 2,034 (1,178) 856 Indefinite-lived intangible assets: In-process research and development ("IPR&D") (1) 59 — 59 92 — 92 Trade names 4 — 4 4 — 4 Total indefinite-lived intangible assets 63 — 63 96 — 96 Total intangible assets $ 2,005 $ (1,292) $ 713 $ 2,130 $ (1,178) $ 952 (1) IPR&D assets are indefinite-lived at the acquisition date until placed into service, at which time such assets will be reclassified to a finite-lived amortizable intangible asset. |
Schedule of Estimated Annual Amortization Expense | The estimated annual amortization expense as of September 29, 2023, was as follows: Fiscal year ending (in millions) 2023 (remainder of year) $ 49 2024 140 2025 113 2026 92 2027 66 2028 and thereafter 190 $ 650 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 9 Months Ended |
Sep. 29, 2023 | |
Fair Value Disclosures [Abstract] | |
Schedule of Financial Assets Measured on a Recurring Basis | The financial instruments measured at fair value on a recurring basis primarily consisted of the following: September 29, 2023 December 30, 2022 Carrying value Fair value Carrying value Fair value (in millions) Financial assets: Derivatives $ 19 $ 19 $ 20 $ 20 |
Derivative Instruments (Tables)
Derivative Instruments (Tables) | 9 Months Ended |
Sep. 29, 2023 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Schedule of Fair Value of the Company's Interest Rate Swaps | The fair value of the interest rate swaps was as follows: Asset derivatives Balance sheet line item September 29, December 30, (in millions) Cash flow interest rate swaps Other long-term assets $ 19 $ 20 |
Schedule of Effect of the Company's Cash Flow Hedges on Other Comprehensive Income and Earnings | The effect of the cash flow hedges on other comprehensive income (loss) and earnings for the periods presented was as follows: Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (in millions) Total interest expense, net presented in the condensed consolidated statements of operations in which the effects of cash flow hedges are recorded $ 53 $ 50 $ 163 $ 148 Amount recognized in other comprehensive income (loss) $ 3 $ 21 $ 11 $ 57 Amount reclassified from accumulated other comprehensive income (loss) to interest expense, net $ (3) $ 2 $ (12) $ 13 |
Debt (Tables)
Debt (Tables) | 9 Months Ended |
Sep. 29, 2023 | |
Debt Disclosure [Abstract] | |
Schedule of Company's Debt | Our debt consisted of the following: Stated interest rate Effective interest rate September 29, December 30, 2022 (in millions) Short-term debt and current portion of long-term debt: Senior unsecured term loans: $380 million term loan, due May 2023 6.08% 6.17% $ — $ 320 Current portion of long-term debt 18 672 Total short-term debt and current portion of long-term debt $ 18 $ 992 Long-term debt: Senior unsecured term loans: $1,925 million term loan, due January 2025 5.77% 6.09% $ — $ 1,211 $1,000 million term loan, due March 2028 6.68% 6.86% 1,000 — Senior unsecured notes: $500 million notes, due May 2023 2.95% 3.17% — 500 $500 million notes, due May 2025 3.63% 3.76% 500 500 $750 million notes due May 2030 4.38% 4.50% 750 750 $750 million notes due March 2033 5.75% 5.81% 750 — $1,000 million notes, due February 2031 2.30% 2.38% 1,000 1,000 $250 million notes, due July 2032 7.13% 7.43% 250 250 $300 million notes, due July 2033 5.50% 5.88% 161 161 $300 million notes, due December 2040 5.95% 6.03% 218 218 Finance leases due on various dates through fiscal 2032 Various 1.84%-6.31% 96 44 Less: unamortized debt discounts and deferred debt issuance costs (40) (34) Total long-term debt 4,685 4,600 Less current portion (18) (672) Total long-term debt, net of current portion $ 4,667 $ 3,928 |
Schedule of Future Minimum Payments of Debt | Future minimum payments of debt are as follows: Fiscal year ending (in millions) 2023 (remainder of year) $ 5 2024 18 2025 619 2026 120 2027 114 2028 and thereafter 3,849 Total principal payments 4,725 Less: unamortized debt discounts and deferred debt issuance costs (40) Total short-term and long-term debt $ 4,685 |
Accumulated Other Comprehensi_2
Accumulated Other Comprehensive Income (Loss) (Tables) | 9 Months Ended |
Sep. 29, 2023 | |
Equity [Abstract] | |
Schedule of Changes in the Components of Accumulated Other Comprehensive Income (Loss) | Changes in the components of Accumulated Other Comprehensive Income (Loss) ("AOCI") were as follows: Foreign currency translation adjustments Unrecognized gain (loss) on derivative instruments Pension adjustments Total AOCI (in millions) Balance at December 31, 2021 $ 22 $ (41) $ 7 $ (12) Other comprehensive income (loss) (108) 59 (27) (76) Taxes 13 (16) 7 4 Reclassification from AOCI — 11 — 11 Balance at December 30, 2022 (73) 13 (13) (73) Other comprehensive income (loss) (22) 11 (1) (12) Taxes 3 — (1) 2 Reclassification from AOCI — (12) — (12) Balance at September 29, 2023 $ (92) $ 12 $ (15) $ (95) |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 9 Months Ended |
Sep. 29, 2023 | |
Earnings Per Share [Abstract] | |
Schedule of Reconciliation of the Weighted Average Number of Shares Outstanding Used to Compute Basic and Diluted EPS | The following table provides a reconciliation of the weighted average number of shares outstanding used to compute basic and diluted EPS for the periods presented: Three Months Ended Nine Months Ended September 29, 2023 (1) September 30, September 29, 2023 (1) September 30, (in millions) Basic weighted average number of shares outstanding 137 137 137 137 Dilutive common share equivalents—stock options and other stock awards — 1 — 1 Diluted weighted average number of shares outstanding 137 138 137 138 |
Business Segments (Tables)
Business Segments (Tables) | 9 Months Ended |
Sep. 29, 2023 | |
Segment Reporting [Abstract] | |
Schedule of Segment Reporting Information by Segment | The segment information for the periods presented was as follows: Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (in millions) Revenues: Defense Solutions $ 2,221 $ 2,075 $ 6,520 $ 6,176 Civil 924 874 2,703 2,526 Health 776 659 2,235 1,997 Total revenues $ 3,921 $ 3,608 $ 11,458 $ 10,699 Operating (loss) income: Defense Solutions $ 147 $ 137 $ 469 $ 409 Civil (607) 79 (503) 160 Health 152 91 381 335 Corporate (28) (26) (87) (81) Total operating (loss) income $ (336) $ 281 $ 260 $ 823 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 9 Months Ended |
Sep. 29, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Schedule of Guaranteed Obligation, Fiscal Year Maturity | As of September 29, 2023, the future expirations of the outstanding letters of credit and surety bonds were as follows: Fiscal year ending (in millions) 2023 (remainder of year) $ 34 2024 10 2025 102 2026 2 2027 13 2028 and thereafter 3 $ 164 |
Basis of Presentation and Sum_4
Basis of Presentation and Summary of Significant Accounting Policies (Narrative) (Details) $ in Millions | 3 Months Ended | 9 Months Ended | |||
Sep. 29, 2023 USD ($) | Sep. 30, 2022 USD ($) | Sep. 29, 2023 USD ($) segment | Sep. 30, 2022 USD ($) | Dec. 30, 2022 USD ($) | |
Significant Accounting Policies [Line Items] | |||||
Number of reportable segments | segment | 3 | ||||
Revenue recognized for performance obligation satisfied in the previous periods | $ 13 | $ 6 | $ 14 | $ 38 | |
Accounts payable and accrued liabilities | 2,221 | 2,221 | $ 2,254 | ||
Restricted cash balances | $ 189 | $ 189 | 167 | ||
Leidos, Inc. | |||||
Significant Accounting Policies [Line Items] | |||||
Controlling ownership interest | 100% | 100% | |||
Cash and Cash Equivalents | |||||
Significant Accounting Policies [Line Items] | |||||
Accounts payable and accrued liabilities | $ 64 | $ 64 | $ 158 |
Basis of Presentation and Sum_5
Basis of Presentation and Summary of Significant Accounting Policies (Changes in Estimates on Contracts) (Details) - USD ($) $ / shares in Units, $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 29, 2023 | Sep. 30, 2022 | Sep. 29, 2023 | Sep. 30, 2022 | |
Accounting Policies [Abstract] | ||||
Favorable impact | $ 40 | $ 36 | $ 102 | $ 116 |
Unfavorable impact | (24) | (29) | (62) | (75) |
Net impact to (loss) income before income taxes | $ 16 | $ 7 | $ 40 | $ 41 |
Impact on diluted EPS attributable to Leidos common stockholders (in dollars per share) | $ 0.09 | $ 0.03 | $ 0.22 | $ 0.22 |
Revenues (Narrative) (Details)
Revenues (Narrative) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 29, 2023 | Sep. 30, 2022 | Sep. 29, 2023 | Sep. 30, 2022 | |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||||
Remaining performance obligations, which are expected to be recognized as revenue | $ 15,500 | $ 15,500 | ||
Revenue recognized under ASC 842 | 24 | $ 29 | 69 | $ 75 |
Contract liability revenue recognized | $ 28 | $ 17 | $ 215 | $ 257 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-09-30 | ||||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||||
Remaining performance obligations, which are expected to be recognized as revenue, period (in months) | 12 months | 12 months | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-09-28 | ||||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||||
Remaining performance obligations, which are expected to be recognized as revenue, period (in months) | 24 months | 24 months | ||
Performance period one | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-09-30 | ||||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||||
Remaining performance obligations, which are expected to be recognized as revenue (as percent) | 63% | 63% | ||
Performance period two | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-09-28 | ||||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||||
Remaining performance obligations, which are expected to be recognized as revenue (as percent) | 79% | 79% |
Revenues (Disaggregation of Rev
Revenues (Disaggregation of Revenue) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 29, 2023 | Sep. 30, 2022 | Sep. 29, 2023 | Sep. 30, 2022 | |
Disaggregation of Revenue [Line Items] | ||||
Revenues | $ 3,897 | $ 3,579 | $ 11,389 | $ 10,624 |
United States | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 3,557 | 3,295 | 10,397 | 9,761 |
International | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 340 | 284 | 992 | 863 |
Cost-reimbursement and fixed-price-incentive-fee | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 1,850 | 1,808 | 5,521 | 5,320 |
Firm-fixed-price | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 1,547 | 1,336 | 4,337 | 4,002 |
Time-and-materials and fixed-price-level-of-effort | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 500 | 435 | 1,531 | 1,302 |
Defense Solutions | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 2,221 | 2,075 | 6,518 | 6,175 |
Defense Solutions | United States | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 1,936 | 1,830 | 5,659 | 5,429 |
Defense Solutions | International | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 285 | 245 | 859 | 746 |
Defense Solutions | Cost-reimbursement and fixed-price-incentive-fee | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 1,247 | 1,166 | 3,578 | 3,493 |
Defense Solutions | Firm-fixed-price | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 718 | 668 | 2,128 | 1,950 |
Defense Solutions | Time-and-materials and fixed-price-level-of-effort | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 256 | 241 | 812 | 732 |
Civil | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 900 | 849 | 2,637 | 2,457 |
Civil | United States | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 845 | 810 | 2,504 | 2,340 |
Civil | International | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 55 | 39 | 133 | 117 |
Civil | Cost-reimbursement and fixed-price-incentive-fee | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 472 | 442 | 1,401 | 1,293 |
Civil | Firm-fixed-price | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 286 | 279 | 813 | 792 |
Civil | Time-and-materials and fixed-price-level-of-effort | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 142 | 128 | 423 | 372 |
Health | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 776 | 655 | 2,234 | 1,992 |
Health | United States | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 776 | 655 | 2,234 | 1,992 |
Health | International | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 0 | 0 | 0 | 0 |
Health | Cost-reimbursement and fixed-price-incentive-fee | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 131 | 200 | 542 | 534 |
Health | Firm-fixed-price | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 543 | 389 | 1,396 | 1,260 |
Health | Time-and-materials and fixed-price-level-of-effort | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 102 | 66 | 296 | 198 |
DoD and U.S. Intelligence Community | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 1,947 | 1,836 | 5,624 | 5,414 |
DoD and U.S. Intelligence Community | Defense Solutions | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 1,677 | 1,559 | 4,798 | 4,620 |
DoD and U.S. Intelligence Community | Civil | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 28 | 22 | 71 | 62 |
DoD and U.S. Intelligence Community | Health | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 242 | 255 | 755 | 732 |
Other U.S. government agencies | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 1,468 | 1,284 | 4,239 | 3,812 |
Other U.S. government agencies | Defense Solutions | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 261 | 236 | 772 | 686 |
Other U.S. government agencies | Civil | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 695 | 676 | 2,054 | 1,949 |
Other U.S. government agencies | Health | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 512 | 372 | 1,413 | 1,177 |
Commercial and non-U.S. customers | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 482 | 459 | 1,526 | 1,398 |
Commercial and non-U.S. customers | Defense Solutions | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 283 | 280 | 948 | 869 |
Commercial and non-U.S. customers | Civil | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 177 | 151 | 512 | 446 |
Commercial and non-U.S. customers | Health | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | $ 22 | $ 28 | $ 66 | $ 83 |
Revenues (Contract Asset and Li
Revenues (Contract Asset and Liabilities) (Details) - USD ($) $ in Millions | Sep. 29, 2023 | Dec. 30, 2022 |
Revenue from Contract with Customer [Abstract] | ||
Contract assets - current: | $ 1,047 | $ 1,010 |
Contract liabilities - current: | 449 | 380 |
Contract liabilities - non-current: | $ 23 | $ 29 |
Acquisitions, Divestitures, G_3
Acquisitions, Divestitures, Goodwill and Intangible Assets (Narrative) (Details) $ in Millions | 3 Months Ended | 9 Months Ended | ||||||
Oct. 30, 2022 USD ($) | Oct. 30, 2022 AUD ($) | Sep. 29, 2023 USD ($) | Sep. 30, 2022 USD ($) | Sep. 29, 2023 USD ($) | Sep. 30, 2022 USD ($) | Dec. 30, 2022 USD ($) | Dec. 31, 2021 USD ($) | |
Restructuring Cost and Reserve [Line Items] | ||||||||
Goodwill | $ 6,079,000,000 | $ 6,079,000,000 | $ 6,696,000,000 | $ 6,744,000,000 | ||||
Goodwill recognized as tax deductible | $ 0 | |||||||
Goodwill impairment charges | 599,000,000 | $ 0 | 599,000,000 | $ 0 | ||||
Amortization expense | 50,000,000 | $ 57,000,000 | 153,000,000 | $ 173,000,000 | ||||
Civil | ||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||
Goodwill | 1,471,000,000 | 1,471,000,000 | $ 2,066,000,000 | $ 2,097,000,000 | ||||
Goodwill impairment charges | 599,000,000 | |||||||
Civil | Security Enterprise Solutions | ||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||
Goodwill | 303,000,000 | 303,000,000 | ||||||
Non-cash goodwill impairment charges | 599,000,000 | 599,000,000 | ||||||
Goodwill impairment charges | 79,000,000 | 79,000,000 | ||||||
Cobham Special Mission | ||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||
Purchase consideration | 192,000,000 | $ 298 | ||||||
Cash acquired in excess of payments to acquire business | $ 10 | |||||||
Cash acquired | 6,000,000 | |||||||
Goodwill | 22,000,000 | |||||||
Property, plant and equipment | $ 148,000,000 | |||||||
Earnings from acquire | $ 28,000,000 | $ 86,000,000 |
Acquisitions, Divestitures, G_4
Acquisitions, Divestitures, Goodwill and Intangible Assets (Intangible Assets Acquired) (Details) - Cobham Special Mission $ in Millions | 9 Months Ended |
Sep. 29, 2023 USD ($) | |
Acquired Indefinite-lived Intangible Assets [Line Items] | |
Weighted average amortization period (in years) | 11 years |
Fair value | $ 24 |
Programs | |
Acquired Indefinite-lived Intangible Assets [Line Items] | |
Weighted average amortization period (in years) | 11 years |
Fair value | $ 19 |
Technology | |
Acquired Indefinite-lived Intangible Assets [Line Items] | |
Weighted average amortization period (in years) | 10 years |
Fair value | $ 5 |
Acquisitions, Divestitures, G_5
Acquisitions, Divestitures, Goodwill and Intangible Assets (Changes in Goodwill by Segment) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||
Sep. 29, 2023 | Sep. 30, 2022 | Sep. 29, 2023 | Sep. 30, 2022 | Dec. 30, 2022 | Dec. 31, 2021 | |
Goodwill [Roll Forward] | ||||||
Beginning balance, goodwill | $ 6,696 | $ 6,744 | $ 6,744 | |||
Acquisition of businesses | 26 | |||||
Divestiture of a business | (6) | |||||
Foreign currency translation adjustments | (14) | (68) | ||||
Goodwill impairment | $ (599) | $ 0 | (599) | 0 | ||
Acquisition of a business | (4) | |||||
Ending balance, goodwill | 6,079 | 6,079 | 6,696 | |||
Defense Solutions | ||||||
Goodwill [Roll Forward] | ||||||
Beginning balance, goodwill | 3,664 | 3,681 | 3,681 | |||
Acquisition of businesses | 26 | |||||
Divestiture of a business | (6) | |||||
Foreign currency translation adjustments | (18) | (37) | ||||
Goodwill impairment | 0 | |||||
Acquisition of a business | (4) | |||||
Ending balance, goodwill | 3,642 | 3,642 | 3,664 | |||
Civil | ||||||
Goodwill [Roll Forward] | ||||||
Beginning balance, goodwill | 2,066 | 2,097 | 2,097 | |||
Acquisition of businesses | 0 | |||||
Divestiture of a business | 0 | |||||
Foreign currency translation adjustments | 4 | (31) | ||||
Goodwill impairment | (599) | |||||
Acquisition of a business | 0 | |||||
Ending balance, goodwill | 1,471 | 1,471 | 2,066 | |||
Accumulated goodwill impairment losses | 716 | 716 | 117 | $ 117 | ||
Health | ||||||
Goodwill [Roll Forward] | ||||||
Beginning balance, goodwill | 966 | $ 966 | 966 | |||
Acquisition of businesses | 0 | |||||
Divestiture of a business | 0 | |||||
Foreign currency translation adjustments | 0 | 0 | ||||
Goodwill impairment | 0 | |||||
Acquisition of a business | 0 | |||||
Ending balance, goodwill | 966 | 966 | 966 | |||
Accumulated goodwill impairment losses | $ 369 | $ 369 | $ 369 | $ 369 |
Acquisitions, Divestitures, G_6
Acquisitions, Divestitures, Goodwill and Intangible Assets (Intangible Assets) (Details) - USD ($) $ in Millions | Sep. 29, 2023 | Dec. 30, 2022 |
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived intangible assets, gross carrying value | $ 1,942 | $ 2,034 |
Finite-lived intangible assets, accumulated amortization | (1,292) | (1,178) |
Finite-lived intangible assets, net carrying value | 650 | 856 |
Indefinite-lived intangible assets | 63 | 96 |
Total intangible assets, gross carrying value | 2,005 | 2,130 |
Total intangible assets, net carrying value | 713 | 952 |
In-process research and development ("IPR&D") | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Indefinite-lived intangible assets | 59 | 92 |
Trade names | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Indefinite-lived intangible assets | 4 | 4 |
Programs | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived intangible assets, gross carrying value | 1,686 | 1,721 |
Finite-lived intangible assets, accumulated amortization | (1,132) | (1,016) |
Finite-lived intangible assets, net carrying value | 554 | 705 |
Software and technology | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived intangible assets, gross carrying value | 203 | 225 |
Finite-lived intangible assets, accumulated amortization | (138) | (136) |
Finite-lived intangible assets, net carrying value | 65 | 89 |
Customer relationships | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived intangible assets, gross carrying value | 52 | 87 |
Finite-lived intangible assets, accumulated amortization | (21) | (25) |
Finite-lived intangible assets, net carrying value | 31 | 62 |
Trade names | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived intangible assets, gross carrying value | 1 | 1 |
Finite-lived intangible assets, accumulated amortization | (1) | (1) |
Finite-lived intangible assets, net carrying value | $ 0 | $ 0 |
Acquisitions, Divestitures, G_7
Acquisitions, Divestitures, Goodwill and Intangible Assets (Estimated Annual Amortization Expense) (Details) - USD ($) $ in Millions | Sep. 29, 2023 | Dec. 30, 2022 |
Estimated Annual Intangible Amortization Expense | ||
2023 (remainder of year) | $ 49 | |
2024 | 140 | |
2025 | 113 | |
2026 | 92 | |
2027 | 66 | |
2028 and thereafter | 190 | |
Finite-lived intangible assets, net carrying value | $ 650 | $ 856 |
Fair Value Measurements (Financ
Fair Value Measurements (Financial Instruments Measured at Fair Value on Recurring Basis) (Details) - USD ($) $ in Millions | Sep. 29, 2023 | Dec. 30, 2022 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Derivative Asset, Statement of Financial Position [Extensible Enumeration] | Other long-term assets | Other long-term assets |
Carrying value | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Derivative asset | $ 19 | $ 20 |
Fair value | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Derivative asset | $ 19 | $ 20 |
Fair Value Measurements (Narrat
Fair Value Measurements (Narrative) (Details) - USD ($) $ in Millions | Sep. 29, 2023 | Dec. 30, 2022 |
Fair value | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair value of debt instrument | $ 4,300 | $ 4,600 |
Carrying value | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair value of debt instrument | 4,700 | 4,900 |
Interest rate swaps | Designated as hedging instrument | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Hedged instrument, face amount | $ 500 | $ 1,000 |
Derivative Instruments (Interes
Derivative Instruments (Interest Rate Swaps) (Details) - USD ($) $ in Millions | Sep. 29, 2023 | Dec. 30, 2022 |
Other long-term assets | Interest rate swaps | Cash flow hedging | ||
Derivative [Line Items] | ||
Asset derivatives | $ 19 | $ 20 |
Derivative Instruments (Narrati
Derivative Instruments (Narrative) (Details) - USD ($) $ in Millions | Sep. 29, 2023 | Dec. 30, 2022 |
Derivative [Line Items] | ||
Gains expected to be reclassified in the next 12 months | $ 13 | |
Interest rate swaps | Designated as hedging instrument | ||
Derivative [Line Items] | ||
Hedged instrument, face amount | $ 500 | $ 1,000 |
Interest rate swap, maturing August 2025 | Designated as hedging instrument | Unsecured debt | ||
Derivative [Line Items] | ||
Stated interest rate (as percent) | 2.96% |
Derivative Instruments (Effect
Derivative Instruments (Effect of Cash Flow Hedge) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 29, 2023 | Sep. 30, 2022 | Sep. 29, 2023 | Sep. 30, 2022 | |
Derivatives, Fair Value [Line Items] | ||||
Total interest expense, net presented in the condensed consolidated statements of operations in which the effects of cash flow hedges are recorded | $ 53 | $ 50 | $ 163 | $ 148 |
Amount recognized in other comprehensive income (loss) | 3 | 21 | 11 | 57 |
Interest expense | ||||
Derivatives, Fair Value [Line Items] | ||||
Amount reclassified from accumulated other comprehensive income (loss) to interest expense, net | $ (3) | $ 2 | $ (12) | $ 13 |
Debt (Schedule of Company's Deb
Debt (Schedule of Company's Debt) (Details) - USD ($) | Sep. 29, 2023 | Dec. 30, 2022 |
Debt Instrument [Line Items] | ||
Current portion of long-term debt | $ 18,000,000 | $ 672,000,000 |
Total short-term debt and current portion of long-term debt | 18,000,000 | 992,000,000 |
Less: unamortized debt discounts and deferred debt issuance costs | (40,000,000) | (34,000,000) |
Total long-term debt | 4,685,000,000 | 4,600,000,000 |
Less current portion | (18,000,000) | (672,000,000) |
Total long-term debt, net of current portion | $ 4,667,000,000 | 3,928,000,000 |
$380 million term loan, due May 2023 | Unsecured debt | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 6.08% | |
Effective interest rate | 6.17% | |
$1,925 million term loan, due January 2025 | Unsecured debt | ||
Debt Instrument [Line Items] | ||
Debt instrument, face amount | $ 1,925,000,000 | |
Stated interest rate | 5.77% | |
Effective interest rate | 6.09% | |
Senior unsecured debt | $ 0 | 1,211,000,000 |
$1,000 million term loan, due March 2028 | Unsecured debt | ||
Debt Instrument [Line Items] | ||
Debt instrument, face amount | $ 1,000,000,000 | |
Stated interest rate | 6.68% | |
Effective interest rate | 6.86% | |
Senior unsecured debt | $ 1,000,000,000 | 0 |
$500 million notes, due May 2023 | Unsecured debt | ||
Debt Instrument [Line Items] | ||
Debt instrument, face amount | $ 500,000,000 | |
Stated interest rate | 2.95% | |
Effective interest rate | 3.17% | |
Senior unsecured debt | $ 0 | 500,000,000 |
$500 million notes, due May 2025 | Unsecured debt | ||
Debt Instrument [Line Items] | ||
Debt instrument, face amount | $ 500,000,000 | |
Stated interest rate | 3.63% | |
Effective interest rate | 3.76% | |
Senior unsecured debt | $ 500,000,000 | 500,000,000 |
$750 million notes due May 2030 | Unsecured debt | ||
Debt Instrument [Line Items] | ||
Debt instrument, face amount | $ 750,000,000 | |
Stated interest rate | 4.38% | |
Effective interest rate | 4.50% | |
Senior unsecured debt | $ 750,000,000 | 750,000,000 |
$750 million notes due March 2033 | Unsecured debt | ||
Debt Instrument [Line Items] | ||
Debt instrument, face amount | $ 750,000,000 | |
Stated interest rate | 5.75% | |
Effective interest rate | 5.81% | |
Senior unsecured debt | $ 750,000,000 | 0 |
$1,000 million notes, due February 2031 | Unsecured debt | ||
Debt Instrument [Line Items] | ||
Debt instrument, face amount | $ 1,000,000,000 | |
Stated interest rate | 2.30% | |
Effective interest rate | 2.38% | |
Senior unsecured debt | $ 1,000,000,000 | 1,000,000,000 |
$250 million notes, due July 2032 | Unsecured debt | ||
Debt Instrument [Line Items] | ||
Debt instrument, face amount | $ 250,000,000 | |
Stated interest rate | 7.13% | |
Effective interest rate | 7.43% | |
Senior unsecured debt | $ 250,000,000 | 250,000,000 |
$300 million notes, due July 2033 | Unsecured debt | ||
Debt Instrument [Line Items] | ||
Debt instrument, face amount | $ 300,000,000 | |
Stated interest rate | 5.50% | |
Effective interest rate | 5.88% | |
Senior unsecured debt | $ 161,000,000 | 161,000,000 |
$300 million notes, due December 2040 | Unsecured debt | ||
Debt Instrument [Line Items] | ||
Debt instrument, face amount | $ 300,000,000 | |
Stated interest rate | 5.95% | |
Effective interest rate | 6.03% | |
Senior unsecured debt | $ 218,000,000 | 218,000,000 |
Finance leases due on various dates through fiscal 2032 | Unsecured debt | ||
Debt Instrument [Line Items] | ||
Finance leases due on various dates through fiscal 2032 | $ 96,000,000 | 44,000,000 |
Finance leases due on various dates through fiscal 2032 | Unsecured debt | Minimum | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 1.84% | |
Finance leases due on various dates through fiscal 2032 | Unsecured debt | Maximum | ||
Debt Instrument [Line Items] | ||
Stated interest rate | 6.31% | |
Unsecured debt | ||
Debt Instrument [Line Items] | ||
Current portion of long-term debt | $ 18,000,000 | 672,000,000 |
Less current portion | (18,000,000) | (672,000,000) |
Unsecured debt | $380 million term loan, due May 2023 | ||
Debt Instrument [Line Items] | ||
Debt instrument, face amount | 380,000,000 | |
Senior unsecured debt | $ 0 | $ 320,000,000 |
Debt (Narrative) (Details)
Debt (Narrative) (Details) | 9 Months Ended | |||||
May 26, 2023 USD ($) | Mar. 10, 2023 USD ($) extension | Feb. 28, 2023 USD ($) | Sep. 29, 2023 USD ($) increase | Mar. 31, 2023 USD ($) | Dec. 30, 2022 aircraft | |
Debt Instrument [Line Items] | ||||||
Commercial paper outstanding | $ 0 | |||||
Flight equipment | ||||||
Debt Instrument [Line Items] | ||||||
Number of aircraft leased | aircraft | 2 | |||||
Finance leases, property, ROU assets | $ 64,000,000 | |||||
Commercial Paper | ||||||
Debt Instrument [Line Items] | ||||||
Debt instrument term (in days) | 397 days | |||||
Debt instrument, increase in commercial paper program | $ 250,000,000 | |||||
Commercial paper | $ 1,000,000,000 | |||||
Minimum denominations of commercial paper | $ 250,000 | |||||
The Credit Agreement | ||||||
Debt Instrument [Line Items] | ||||||
Number of additional extensions | extension | 2 | |||||
Debt instrument, extension term (in years) | 1 year | |||||
Covenant, adjusted consolidated total debt to consolidated EBITDA ratio | 3.75 | |||||
Number of potential leverage ratio increases | increase | 2 | |||||
Covenant, leverage ratio, maximum, potential increase following material acquisition | 4.50 | |||||
Covenant, consolidated EBITDA to interest expense ratio | 3.50 | |||||
The Credit Agreement | SOFR | ||||||
Debt Instrument [Line Items] | ||||||
Variable rate (as percent) | 1.25% | |||||
The Credit Agreement | SOFR | Minimum | ||||||
Debt Instrument [Line Items] | ||||||
Variable rate (as percent) | 1% | |||||
The Credit Agreement | SOFR | Maximum | ||||||
Debt Instrument [Line Items] | ||||||
Variable rate (as percent) | 1.50% | |||||
Term loan | Unsecured debt | SOFR | ||||||
Debt Instrument [Line Items] | ||||||
Variable rate (as percent) | 0.10% | |||||
Notes maturing March 2033 | Unsecured debt | ||||||
Debt Instrument [Line Items] | ||||||
Debt instrument, face amount | $ 750,000,000 | |||||
Debt interest rate (as percent) | 5.75% | |||||
Amortization of debt discount and debt issuance costs | $ 11,000,000 | |||||
Notes maturing 2023 | Unsecured debt | ||||||
Debt Instrument [Line Items] | ||||||
Debt instrument, face amount | $ 500,000,000 | |||||
Notes maturing 2023 | Unsecured debt | ||||||
Debt Instrument [Line Items] | ||||||
Debt interest rate (as percent) | 2.95% | |||||
Term loan | The Credit Agreement | Unsecured debt | ||||||
Debt Instrument [Line Items] | ||||||
Debt instrument, face amount | $ 1,000,000,000 | $ 1,900,000,000 | ||||
Repayment of term loan | $ 210,000,000 | |||||
Revolving credit facility | The Credit Agreement | Line of credit | ||||||
Debt Instrument [Line Items] | ||||||
Unsecured borrowing capacity | $ 1,000,000,000 | 750,000,000 | ||||
Long-term line of credit | $ 0 |
Debt (Maturities of Notes Payab
Debt (Maturities of Notes Payable and Long-Term Debt) (Details) - USD ($) $ in Millions | Sep. 29, 2023 | Dec. 30, 2022 |
Debt Disclosure [Abstract] | ||
2023 (remainder of year) | $ 5 | |
2024 | 18 | |
2025 | 619 | |
2026 | 120 | |
2027 | 114 | |
2028 and thereafter | 3,849 | |
Total principal payments | 4,725 | |
Less: unamortized debt discounts and deferred debt issuance costs | 40 | $ 34 |
Total short-term and long-term debt | $ 4,685 |
Accumulated Other Comprehensi_3
Accumulated Other Comprehensive Income (Loss) - Schedule of Changes in the Components of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions | 9 Months Ended | 12 Months Ended |
Sep. 29, 2023 | Dec. 30, 2022 | |
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||
Beginning balance | $ 4,353 | $ 4,344 |
Other comprehensive income (loss) | (12) | (76) |
Taxes | 2 | 4 |
Reclassification from AOCI | (12) | 11 |
Ending balance | 4,203 | 4,353 |
Total AOCI | ||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||
Beginning balance | (73) | (12) |
Ending balance | (95) | (73) |
Foreign currency translation adjustments | ||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||
Beginning balance | (73) | 22 |
Other comprehensive income (loss) | (22) | (108) |
Taxes | 3 | 13 |
Reclassification from AOCI | 0 | 0 |
Ending balance | (92) | (73) |
Unrecognized gain (loss) on derivative instruments | ||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||
Beginning balance | 13 | (41) |
Other comprehensive income (loss) | 11 | 59 |
Taxes | 0 | (16) |
Reclassification from AOCI | (12) | 11 |
Ending balance | 12 | 13 |
Pension adjustments | ||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||
Beginning balance | (13) | 7 |
Other comprehensive income (loss) | (1) | (27) |
Taxes | (1) | 7 |
Reclassification from AOCI | 0 | 0 |
Ending balance | $ (15) | $ (13) |
Earnings Per Share (Reconciliat
Earnings Per Share (Reconciliation of Weighted Average Number of Shares Outstanding) (Details) - shares shares in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 29, 2023 | Sep. 30, 2022 | Sep. 29, 2023 | Sep. 30, 2022 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Basic weighted average number of shares outstanding (in shares) | 137 | 137 | 137 | 137 |
Dilutive common share equivalents-stock options and other stock awards (in shares) | 0 | 1 | 0 | 1 |
Diluted weighted average number of shares outstanding (in shares) | 137 | 138 | 137 | 138 |
Anti-dilutive shares (in shares) | 2 | 1 | 2 | 1 |
Equity awards | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Anti-dilutive shares (in shares) | 1 | 1 |
Earnings Per Share (Narrative)
Earnings Per Share (Narrative) (Details) - USD ($) shares in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 29, 2023 | Sep. 30, 2022 | Sep. 29, 2023 | Sep. 30, 2022 | |
Earnings Per Share [Abstract] | ||||
Anti-dilutive shares (in shares) | 2 | 1 | 2 | 1 |
Payments for repurchase of common stock | $ 0 | $ 25,000,000 |
Income Taxes (Details)
Income Taxes (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 29, 2023 | Sep. 30, 2022 | Sep. 29, 2023 | Sep. 30, 2022 | |
Income Tax Disclosure [Abstract] | ||||
Effective tax rate (as percent) | (2.10%) | 25.80% | 123.70% | 23.20% |
Unrecognized tax benefits, increase | $ 71 |
Business Segments (Segment Repo
Business Segments (Segment Reporting Information by Segment) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 29, 2023 | Sep. 30, 2022 | Sep. 29, 2023 | Sep. 30, 2022 | |
Segment Reporting Information [Line Items] | ||||
Total revenues | $ 3,921 | $ 3,608 | $ 11,458 | $ 10,699 |
Total operating (loss) income | (336) | 281 | 260 | 823 |
Corporate | ||||
Segment Reporting Information [Line Items] | ||||
Total operating (loss) income | (28) | (26) | (87) | (81) |
Defense Solutions | Operating Segments | ||||
Segment Reporting Information [Line Items] | ||||
Total revenues | 2,221 | 2,075 | 6,520 | 6,176 |
Total operating (loss) income | 147 | 137 | 469 | 409 |
Civil | Operating Segments | ||||
Segment Reporting Information [Line Items] | ||||
Total revenues | 924 | 874 | 2,703 | 2,526 |
Total operating (loss) income | (607) | 79 | (503) | 160 |
Health | Operating Segments | ||||
Segment Reporting Information [Line Items] | ||||
Total revenues | 776 | 659 | 2,235 | 1,997 |
Total operating (loss) income | $ 152 | $ 91 | $ 381 | $ 335 |
Commitments and Contingencies_2
Commitments and Contingencies (Narrative) (Details) | 1 Months Ended | ||||||
Oct. 30, 2020 USD ($) | Nov. 22, 2019 USD ($) patent | Aug. 30, 2018 USD ($) | Apr. 10, 2018 USD ($) | Jan. 31, 2021 USD ($) | Sep. 29, 2023 USD ($) | Aug. 31, 2022 government_procurement | |
Legal Proceedings [Line Items] | |||||||
Number of government procurements | government_procurement | 3 | ||||||
Standby letters of credit | |||||||
Legal Proceedings [Line Items] | |||||||
Amount outstanding | $ 60,000,000 | ||||||
Performance guarantee | |||||||
Legal Proceedings [Line Items] | |||||||
Surety bonds notional amount | $ 104,000,000 | ||||||
Virnet X Inc | |||||||
Legal Proceedings [Line Items] | |||||||
Amount awarded from other party | $ 503,000,000 | $ 595,000,000 | $ 502,000,000 | $ 502,000,000 | |||
Royalty rate awarded (per device) | $ 0.84 | 1.20 | |||||
Awarded to the other party, interest and legal fees | $ 93,000,000 | ||||||
Number of infringed patents | patent | 2 | ||||||
Number of infringed other patents | patent | 2 | ||||||
Additional costs and interest | $ 75,000,000 | ||||||
Leidos | |||||||
Legal Proceedings [Line Items] | |||||||
Litigation settlement, percentage of total (as percent) | 25% |
Commitments and Contingencies_3
Commitments and Contingencies (Future Expirations Maturity Table) (Details) - Standby Letters of Credit and Surety Bonds $ in Millions | Sep. 29, 2023 USD ($) |
Guaranteed Obligation, Type [Line Items] | |
2023 (remainder of year) | $ 34 |
2024 | 10 |
2025 | 102 |
2026 | 2 |
2027 | 13 |
2028 and thereafter | 3 |
Total | $ 164 |